EP3223824A1 - Oxidized lipids and treatment or prevention of fibrosis - Google Patents

Oxidized lipids and treatment or prevention of fibrosis

Info

Publication number
EP3223824A1
EP3223824A1 EP15863247.1A EP15863247A EP3223824A1 EP 3223824 A1 EP3223824 A1 EP 3223824A1 EP 15863247 A EP15863247 A EP 15863247A EP 3223824 A1 EP3223824 A1 EP 3223824A1
Authority
EP
European Patent Office
Prior art keywords
fibrosis
group
formula
phosphoryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15863247.1A
Other languages
German (de)
French (fr)
Other versions
EP3223824B1 (en
EP3223824A4 (en
Inventor
Itzhak Mendel
Yaniv Salem
Niva Yacov
Eyal Breitbart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Notable Labs Ltd
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of EP3223824A1 publication Critical patent/EP3223824A1/en
Publication of EP3223824A4 publication Critical patent/EP3223824A4/en
Application granted granted Critical
Publication of EP3223824B1 publication Critical patent/EP3223824B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides

Definitions

  • the present invention relates to methods of treating or preventing fibrosis with oxidized lipid compounds and pharmaceutical compositions comprising the same.
  • Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue.
  • Fibrosis encompasses the pathological state of excess deposition of fibrous tissue, as well as the process of connective tissue deposition in healing. Fibrosis is similar to the process of scarring, in that both involve stimulated cells (e.g., fibroblasts) laying down connective tissue, including collagen and glycosaminoglycans.
  • stimulated cells e.g., fibroblasts
  • Fibrosis can be considered as a scarring process in response to chronic diseases where excessive extracellular matrix (ECM) deposition leads to irreversible tissue damage and failure or disturbance of proper organ function.
  • ECM extracellular matrix
  • the pathophysiology of fibrosis has generally been studied in the context of the particular organ or tissue affected, including lung, kidney, liver, heart and skin. Loss of metabolic homeostasis and chronic low-grade inflammation may play a role in the pathogenesis of fibrosis.
  • Fibrogenesis is a dynamic process and occurs in four phases: i) initiation, due to injury of the organ/tissue; ii) inflammation and activation of effector cells; iii) enhanced synthesis of ECM; and iv) deposition of ECM with progression to end-organ failure.
  • Fibrosis can occur in many tissues within the body. Examples include pulmonary fibrosis (lungs), idiopathic pulmonary fibrosis (lungs), cystic fibrosis (lungs), progressive massive fibrosis (lungs), liver fibrosis, cirrhosis (liver), steatohepatitis (fatty liver disease), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), endomyocardial fibrosis (heart), myocardial infarction (heart), atrial fibrosis (heart), medastinal fibrosis (soft tissue of mediastinum), myelofibrosis (bone marrow), retroperitoneal fibrosis (soft tissue of the retroperitoneum), nephrogenic systemic fibrosis (skin), keloid (skin), Crohn's disease (intestine), scleroderma/systemic sclerosis (skin, lungs), arthrofibrosis (knee
  • NASH nonalcoholic fatty liver disease
  • TLRs toll-like receptors
  • TLRs are a family of receptors imperative for the innate immune response against microbial invasion. TLRs can be divided into two major subgroups based on their cellular localization. Plasma membrane expressed TLRs include TLR1, TLR2, TLR4, TLR5 and TLR6, whereas the intracellular TLRs include TLR3, TLR7, TLR8 and TLR9.
  • the interaction between TLRs with their cognate agonists instigates a cascade of cues which include recruitment of the adaptor molecules MyD88/TRIF and downstream phosphorylation of MAPK kinases and NF- ⁇ . These events culminate in the secretion of proinflammatory cytokines, including IL- 12/23, IL-6 and TNF-a.
  • TLR2 forms a heterodimer with TLR1 which recognizes bacterial triacylated lipopeptides, and a heterodimer with TLR6 which recognizes bacterial diacylated lipopeptides.
  • LBP lipopolysaccharide-binding protein
  • LPS lipopoly saccharide
  • Liver resident kupffer and hepatic stellate cells express TLR2 which recognize triacylated lipopeptides from Gram-negative bacteria and mycoplasma and diacylated lipopeptides from Gram-negative bacteria and mycoplasma and TLR4 and its co-receptor CD14 which recognize lipopolysaccharide (LPS) from gram-negative bacteria.
  • TLR2 and TLR4 can also bind to danger associated molecular patterns released from injured tissues.
  • TLR2 and TLR4 complexes mediate the production of pro-inflammatory cytokines and fibrogenic response by kupffer and stellate cells.
  • Monocytes are key players in the immune system, with critical roles in innate and adaptive immunity, immune surveillance and particle scavenging. Whereas a subset of monocytes is “resident" and recruited to tissues independently of inflammatory stimuli to assist in steady-state surveillance, wound-healing and resolution of inflammation, the absolute majority (80-90%) of human circulating monocytes is classified as "inflammatory". These monocytes can sense inflammatory stimuli and quickly migrate through the vascular or lymphatic endothelium to the periphery, where they can differentiate into macrophages and dendritic cells (DCs) which cooperate with additional cell subsets (such as Thl-cells) to promote inflammation.
  • DCs dendritic cells
  • monocytes While playing a necessary role in host defense, monocytes were nonetheless identified as critical mediators of several inflammatory diseases, including atherosclerosis, rheumatoid arthritis (RA) and multiple sclerosis (MS). Suppressing the accumulation of unwanted monocytes/macrophages in a chronically inflamed tissue has therapeutic potential, and migration inhibitors have accordingly demonstrated promising anti-inflammatory results in animal models and clinical trials.
  • RA rheumatoid arthritis
  • MS multiple sclerosis
  • Renal fibrosis is a wound healing/scarring response following kidney injury that occurs in many forms of chronic kidney disease (CKD). Following kidney injury, resident fibroblasts are activated by various pro-inflammatory and pro- fibrotic stimuli. Activated fibroblasts, also called myofibroblasts, produce excessive ECM proteins that accumulate in the interstitium, and therefore are considered a mediator of renal fibrosis. Regardless of the primary insult leading to renal fibrosis, chronic inflammation appears to be a process heralding renal fibrogenesis. Elevated levels of inflammatory markers were associated with an increased risk of developing CKD.
  • TLRs and macrophages are associated with the pathogenesis of renal fibrosis.
  • Fibrosis can cause severe morbidity and deleterious effects on patients' daily function, activity of daily living (ADL) and quality of life, and can lead to poor prognosis.
  • idiopathic pulmonary fibrosis PF
  • IPF patients become oxygen dependent, and have an average median survival time of three years and a five year survival rate of 20% to 40% after diagnosis. Therefore, the development of new therapies for fibrosis is needed.
  • the present invention provides methods of treating or preventing fibrosis (e.g., liver fibrosis, kidney fibrosis, focal and segmental glomerulosclerosis, or any other fibrosis described herein), comprising administering to a subject in need thereof a therapeutically effective amount of a compound having a structure according to Formula 1 :
  • fibrosis e.g., liver fibrosis, kidney fibrosis, focal and segmental glomerulosclerosis, or any other fibrosis described herein
  • n is an integer from 1 to 6, wherein when n is 1, Cn, Bn, Rn, and Y are absent, and
  • each of Bi, B 2 , ...Bn-1 and Bn is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, wherein each of said nitrogen, phosphorus and silicon is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy, and oxo;
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4, 5 -biphosphonate, phosphoinositol-4, 5 -bi sphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, phosphoglycerol and
  • each of B' and B" is independently selected from the group consisting of sulfur and oxygen;
  • each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate, and thiophosphonate;
  • each of Xi, X 2 , ...Xn-1 is independently a saturated or unsaturated hydrocarbon having the general Formula 2: Ra Rb Rm-1 Rm
  • n is an integer from 1 to 26;
  • Z is selected from the group consisting of:
  • W is selected from the group consisting of oxygen and sulfur
  • Rb, ...Rm-1, R'm-1, Rm and Rm is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aiyloxy, thiohydroxy, thioalkoxy, thioaiyloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O- carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of Ri, R'i, R2, ...Rn-1, Rn and Rn and/or at least two of Ra, Ra, Rb, R'b, ...Rm-1, R'm-1
  • the compound is l-hexadecyl-2-(4'-carboxybutyl)-glycero-
  • the compound is (R)-l-hexadecyl-2- (4'-carboxybutyl)-sn-glycero-3-phosphocholine. In other embodiments, the compound has the following structure:
  • the compound has the following structure:
  • FIGs. 1A-1D show VB-201 inhibits lipopolysacchande (LPS) (TLR4)-induced signaling in human monocytes (primary CD 14+).
  • LPS lipopolysacchande
  • FIGs. 2A-2B show VB-201 inhibits PGN (TLR2)-induced signaling in human monocytes (THP-1 cell line).
  • FIG. 3 shows VB-201 inhibits MCP-1 -induced signaling in human monocytes
  • THP-1 cell line THP-1 cell line
  • FIG. 4 shows VB-201 inhibits chemokine-induced migration of human monocytes
  • FIG. 5 shows VB-201 inhibits SDF1 -induced cell migration of human monocytes
  • THP-1 cell line THP-1 cell line
  • FIG. 6 shows VB-201 inhibits RANTES-induced signaling in human monocytes
  • FIGs. 7A-7B show VB-201 inhibits IL-12p40 levels in human monocytes
  • FIG. 8 shows the effect of VB-201 on LPS-binding by human primary monocytes.
  • FIG. 9 shows VB-201 inhibits IL-6 secretion in LPS (TLR4)-stimulated human monocytes derived dendritic cells (Mo-derived DCs).
  • FIG. 10 shows VB-201 inhibits IL-12p40 secretion in LPS (TLR4)-stimulated human Mo-derived DCs.
  • FIGs. 11A-11B show the effect of VB-201 on liver inflammation (FIG. 11 A).
  • NASH was induced by injection of mice with 200 ⁇ g streptozotocin (STZ) two days after birth and by feeding a high fat diet (HFD) from four weeks of age. Mice were then either treated with vehicle (negative control), VB-201 (4 mg/kg), or telmisartan (10 mg/kg; positive control) at six weeks of age for three weeks, or not treated (Normal). Mice were sacrificed at nine weeks of age.
  • FIG. 11B shows H&E stained liver samples following treatment (200X magnification).
  • FIGs. 12A-12B show the effect of VB-201 on liver fibrosis. NASH was induced as explained in FIGs. 1 lA-1 IB. Staining of liver histological samples with Sirius red was used to determine the extent of fibrosis.
  • FIG. 12B shows Sirius red staining of liver samples following treatment (200X magnification).
  • FIG. 13 presents bar graphs showing the effect of VB-201 in reducing the number of damaged glomeruli (%) in a renal fibrosis model.
  • Abbreviations are: Nx, nephrectomized; Eth, ethanol.
  • FIG. 14 presents bar graphs showing the effect of VB-201 in reducing glomerular sclerosis (%).
  • nephrectomized rats treated with solvent control (0.5%) ethanol/PBS) is presented as follows: * represents p ⁇ 0.05; ** represents p ⁇ 0.005; and *** represents p ⁇ 0.001.
  • Abbreviations are: Nx, nephrectomized; Eth, ethanol.
  • FIG. 15 presents PAS staining (x400) images showing the effect of VB-201 in reducing glomerular sclerosis. Renal morphology was assessed by light microscope in PAS stained sections of healthy rats (Healthy x400), sham operated rats (Sham x400), nephrectomized rats treated with solvent control (0.5% ethanol/PBS) (Nx PBS 0.5% Eth x400), nephrectomized rats VB-201 4 mg/kg treated (Nx VB-201 4 mg/kg x400) or nephrectomized rats telmisartan 10 mg/kg treated (Nx Telmisartan 10 mg/kg x400) at 8 weeks following the first surgery. Abbreviations are: Nx, nephrectomized; Eth, ethanol, PAS, Periodic Acid-Schiff.
  • FIGs. 16A-16C show the effect of VB-201 on monocyte/macrophage cell infiltration in the glomeruli (FIG. 16A) or in the interstitium (FIG. 16B).
  • FIG. 16C presents representative CD68 staining (x400) images showing the effect of VB-201 in reducing the number of CD68 cells. Abbreviations are: Nx, nephrectomized; Eth, ethanol.
  • FIGs. 17A-17B present bar graphs showing the effect of VB-201 on pro-fibrotic markers.
  • Relative expression of Collagen IV (FIG. 17A) and TGF- ⁇ (FIG. 17B) in the kidney was evaluated in healthy rats (white bar), sham operated rats (white bar with stripes), nephrectomized rats treated with solvent control (0.5% ethanol/PBS) (black bar), nephrectomized rats VB-201 4 mg/kg treated (light gray bar) or nephrectomized rats telmisartan 10 mg/kg treated (dark gray bar) at 8 weeks.
  • nephrectomized rats treated with solvent control (0.5% ethanol/PBS) is presented as follows: in FIG. 17A, * represents p ⁇ 0.05; and in FIG. 17B, * represents p ⁇ 0.001.
  • Abbreviations are: Nx, nephrectomized; Eth, ethanol.
  • FIG. 18 presents bar graphs showing that VB-201 inhibits IL-12/23p40 expression in livers of NASH-induced mice.
  • Mice were induced for NASH and VB-201 was administered orally at a dose of 4 mg/kg once daily from Week 6 to Week 9.
  • Telmisartan was administered at a dose of 10 mg/kg once daily.
  • Q-PCR was used to detect IL-12/23p40.
  • GAPDH was used to normalize RNA levels.
  • Analysis of IL- 12/23p40 in the livers of NASH-induced mice shows that VB-201 significantly attenuated the expression of IL- 12/23 p40, with p ⁇ 0.05.
  • the term "about” modifying an amount related to the invention refers to variation in the numerical quantity that can occur, for example, through routine testing and handling; through inadvertent error in such testing and handling; through differences in the manufacture, source, or purity of ingredients employed in the invention; and the like. Whether or not modified by the term “about”, the claims include equivalents of the recited quantities. In one embodiment, the term “about” means within 10% of the reported numerical value.
  • a therapeutically effective amount refers to that amount of a given therapeutic agent sufficient to result in amelioration of one or more symptoms of a disorder or condition, or prevent appearance or advancement of a disorder or condition, or cause regression of or cure from the disorder or condition.
  • a therapeutically effective amount of VB-201 is about 5 mg to about 160 mg VB-201 per day.
  • alkyl refers to a saturated aliphatic hydrocarbon including straight chain and branched chain groups.
  • the alkyl group has 1 to 20 carbon atoms. Whenever a numerical range; e.g., " 1-20", is stated herein, it implies that the group, in this case the alkyl group, may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms.
  • the alkyl is a medium size alkyl having 1 to 10 carbon atoms.
  • the alkyl is a lower alkyl having 1 to 4 carbon atoms.
  • the alkyl group can be substituted (e.g., with 1 to 5 substituent groups) or unsubstituted. In any of the embodiments described herein, the alkyl can be unsubstituted. In any of the embodiments described herein, the alkyl can also be substituted by one to five substituent groups, wherein the substituent group can be, for example, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, sulfonyl, sulfinyl, sulfonamide, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl,
  • a "cycloalkyl” group refers to an all-carbon monocyclic or fused ring (i.e., rings which share an adjacent pair of carbon atoms) group wherein one of more of the rings does not have a completely conjugated pi-electron system.
  • examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, cycloheptane, cycloheptatriene, and adamantane.
  • a cycloalkyl group can be substituted (e.g., with 1 to 5 substituent groups) or unsubstituted.
  • the cycloalkyl can be unsubstituted.
  • the cycloalkyl can also be substituted by one to five substituent groups, wherein the substituent group can be, for example, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, sulfonyl, sulfinyl, sulfonamide, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O- carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amid
  • alkenyl refers to an aliphatic hydrocarbon group which contains at least two carbon atoms and at least one carbon-carbon double bond, which can be straight or branched.
  • An alkenyl group can be substituted or unsubstituted.
  • alkynyl refers to an aliphatic hydrocarbon group which contains at least two carbon atoms and at least one carbon-carbon triple bond.
  • An alkynyl group can be substituted or unsubstituted.
  • aryl group refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups having a completely conjugated pi-electron system.
  • aryl groups can have 6 to 14 carbons, e.g., 6 tolO carbons. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl.
  • the aryl group can be substituted (e.g., with 1 to 5 substituent groups) or unsubstituted.
  • the substituent group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, sulfonyl, sulfinyl, sulfonamide, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, and amino, as these terms are defined herein.
  • the aryl group can be a phenyl group, optionally substituted, for example, by one to five substituent such as halogens (e.g., fluorine or chlorine), alkyl groups (e.g., a C 1-4 alkyl), or halogen substituted alkyls (e.g., trifluoromethyl).
  • substituents e.g., fluorine or chlorine
  • alkyl groups e.g., a C 1-4 alkyl
  • halogen substituted alkyls e.g., trifluoromethyl
  • heteroaryl group refers to a monocyclic or fused ring (i.e., rings which share an adjacent pair of atoms) group having in the ring(s) one or more atoms, such as, for example, nitrogen, oxygen and sulfur and, in addition, having a completely conjugated pi- electron system.
  • heteroaryl groups can have 5 to 14 ring atoms, e.g., 5 to 10 ring atoms (e.g., 5 or 6 ring atoms).
  • heteroaryl groups examples include pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline and purine.
  • the heteroaryl group can be substituted (e.g., with 1 to 5 substituent groups) or unsubstituted.
  • the substituent group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, sulfonyl, sulfinyl, sulfonamide, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O- carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, and amino, as these terms are defined herein.
  • heteroalicyclic group refers to a monocyclic or fused ring group having in the ring(s) one or more heteroatoms such as nitrogen, oxygen and sulfur.
  • the rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system.
  • heteroalicyclic groups can have 3 to 10 ring atoms, e.g., 5 to 10 ring atoms (e.g., 5 or 6 ring atoms).
  • the heteroalicyclic can be substituted (e.g., with 1 to 5 substituent groups) or unsubstituted.
  • the substituted group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, heteroalicyclic, halo, hydroxy, alkoxy, aiyloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, sulfonyl, sulfinyl, sulfonamide, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O- carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, and amino, as these terms are defined herein. Representative examples are
  • alkoxy group refers to both an -O-alkyl and an -O-cycloalkyl group, wherein the alkyl or cycloalkyl can be any of those as defined herein.
  • an "aiyloxy” group refers to both an -O-aiyl and an -O-heteroaiyl group, wherein the aryl or heteroaiyl can be any of those as defined herein.
  • a "thiohydroxy” group refers to a -SH group.
  • a "thioalkoxy" group refers to both an -S-alkyl group, and an -S-cycloalkyl group, wherein the alkyl or cycloalkyl can be any of those as defined herein.
  • a "thioaryloxy” group refers to both an -S-aryl and an -S-heteroaryl group, wherein the aryl or heteroaiyl can be any of those as defined herein.
  • aldehyde refers to a carbonyl group, wherein R is hydrogen.
  • a "carboxylic acid” group refers to a C-carboxyl group in which R is hydrogen.
  • halo group or halogen refers to fluorine, chlorine, bromine or iodine.
  • a "trihalomethyl” group refers to a -CX 3 group wherein X is a halo group as defined herein, e.g., a CF 3 group.
  • amino group refers to an - R 2 group wherein each of R is as defined herein.
  • a "phosphoric acid” is a phosphate group wherein each of R is hydrogen.
  • phosphinyl describes a -PR 2 group, with each of R as defined herein.
  • saccharide refers to one or more sugar units, either an open-chain sugar unit or a cyclic sugar unit (e.g., pyranose- or furanose-based units), and encompasses any monosaccharide, disaccharide and oligosaccharide, unless otherwise indicated.
  • stereoisomer includes geometric isomers, such as E or Z isomers, enantiomers, diastereomers, and the like.
  • stereoisomeric mixture includes any mixture in any ratio of stereoisomers defined herein.
  • a stereoisomeric mixture includes a racemic mixture.
  • a stereoisomeric mixture includes an enantiomerically enriched mixture.
  • a stereoisomeric mixture includes a mixture of diastereomers in any ratio.
  • enantiomeric excess refers to a measure for how much of one enantiomer is present compared to the other.
  • percent enantiomeric excess is defined as
  • * 100, where R and S are the respective mole or weight fractions of enantiomers in a mixture such that R + S 1.
  • the percent enantiomeric excess is defined as ([ ] ObS /[a]max)* 100, where [ ] 0bS is the optical rotation of the mixture of enantiomers and [a] ma x is the optical rotation of the pure enantiomer.
  • salt includes both internal salt or external salt.
  • the salt is an internal salt, i.e., a zwitterion structure.
  • the salt is an external salt.
  • the external salt is a pharmaceutically acceptable salt having a suitable counter ion. Suitable counterions for pharmaceutical use are known in the art.
  • an oxidized lipid on the invention is a compound having a structure according to Formula 1 :
  • n is an integer from 1 to 6, wherein when n is 1, Cn, Bn, Rn, and Y are absent, and
  • each of Bi, B 2 , ...Bn-1 and Bn is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, wherein each of said nitrogen, phosphorus and silicon is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo;
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4, 5 -biphosphonate, phosphoinositol-4, 5 -bi sphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, phosphoglycerol and
  • each of B' and B" is independently selected from the group consisting of sulfur and oxygen;
  • each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate;
  • each of Xi, X 2 , ...Xn-1 is independently a saturated or unsaturated hydrocarbon having the general Formula 2: Ra Rb Rm-1 Rm
  • n is an integer from 1 to 26;
  • Z is selected from the group consisting of:
  • W is selected from the group consisting of oxygen and sulfur
  • Rb, ...Rm-1, Rm-1, Rm and Rm is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aiyloxy, thiohydroxy, thioalkoxy, thioaiyloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O- carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of Ri, R'i, R2, ...Rn-1, Rn and Rn and/or at least two of Ra, Ra, Rb, R'b, ...Rm-1, Rm-1, R
  • an oxidized lipid on the invention is a compound having a structure according to Formula 3 :
  • n is an integer selected from 1 to 4.
  • each B 2 , and B 3 are independently selected from the group consisting of oxygen, sulfur, and R 4 , wherein R 4 is selected from hydrogen, alkyl, cycloalkyl, aryl, and acyl.
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol, and a moiety having the general formula:
  • each of B' and B" is independently selected from the group consisting of sulfur and oxygen;
  • D' and D" are independently selected from the group consisting of hydrogen, alkyl, aminoalkyl, cycloalkyl, phosphonate and thiophosphonate.
  • Xi and each X 2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of X 1 and X 2 is substituted with an oxidized moiety Z selected from the group consisting of:
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
  • m is an integer selected from 1 to 26.
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl,
  • Rc and Rc C are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, tnhalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C- carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, wherein at least two of Ri, Ria, R 2 , R 3 and R 3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring, and wherein at least two of R
  • n is 1 or 2. In another embodiment in Formula 3, n is 1 or 2.
  • n 1
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
  • Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine.
  • Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
  • Y is phosphoryl choline.
  • Z is ' .
  • Z is a carboxylic acid group.
  • n 1 and Y is phosphoryl choline.
  • each of Bi, B 2 , and B 3 is oxygen.
  • n is 1
  • Y is phosphoryl choline
  • Bi, B 2 , and B 3 is oxygen.
  • the oxidized phospholipid useful in any of the methods of the present disclosure has a structure according to Formula 3a:
  • Bi, B 2 , and B 3 are independently selected from oxygen and sulfur.
  • a 1 and A 2 are independently selected from the group consisting of
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol, and a moiety having the general formula:
  • each of B' and B" is independently selected from the group consisting of sulfur and oxygen;
  • each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate.
  • Ri, Ri a , R 2 , R 3 , and R 3a are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S- thiocarboxy and amino, wherein at least two of Ri, Ri a , R 2 , R 3 and R 3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic
  • Xi and X 2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of Xi and X 2 is substituted with an oxidized moiety Z having a formula selected from:
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
  • Xi and X 2 independently have a structure according to Formula 4a:
  • m is an integer selected from 1 to 26.
  • R a , Raa, each R , each R b , Rc, and Rc C are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C- thiocarboxy, S-thiocarboxy and amino, wherein at least two of R a , R aa , R b , R bb , Rc, and Rcc are optionally joined to form
  • Z is selected from the group consisting of:
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaiyl, wherein at least one of Xi and X 2 comprises a Z other than hydrogen.
  • Z is In another embodiment in Formula 3a, Z is In another embodiment in
  • Formula 3a Z is a carboxylic acid group.
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)] , phosphoinositol-4-phosphate, phosphoinositol-4, 5 -bi sphosphate, phosphoethanolamine-diethylenetriamine-pentacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
  • Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine.
  • Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
  • Y is phosphoryl choline.
  • each of Bi, B 2 , and B 3 is oxygen.
  • Y is phosphoryl choline, and each of Bi,
  • B 2 , and B 3 is oxygen.
  • the oxidized phospholipid has a structure according to Formula 4b:
  • each of Bi, B 2 , B 3 in Formula 4b is oxygen and the oxidized phospholipid has a structure according to the Formula 4c:
  • a 1 in Formula 4c is CH 2 .
  • a 2 is absent or CH 2 .
  • X 1 is an alkyl having from 1 to 30 carbon atoms.
  • E is absent or is an alkyl chain having from 1 to 24 carbon atoms
  • F is selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halide, acetoxy and aryl;
  • Z is selected from the group consisting of:
  • R d is selected from H, alkyl and aryl.
  • Y is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N- [methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5- bisposphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentacetate, dinitrophenyl-phosphoethanolamine, phospho
  • each of B' and B" is independently selected from the group consisting of sulfur and oxygen;
  • each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate.
  • X 1 is alkyl having from 10 to 30 carbon atoms, or from 8 to 30 carbon atoms.
  • E is alkyl having from 1 to 10 carbon atoms, or from 1 to 4 carbon atoms.
  • Y is phosphoryl choline.
  • Each carbon atom in Formula 1, 2, 3, 3a, 4b and 4c is a chiral or non-chiral carbon atom, wherein each chiral carbon atom can have S-configuration or R-configuration.
  • the oxidized lipid is l-hexadecyl-2-(4'-carboxy)butyl- glycero-3 -phosphocholine or 1 -hexadecyl-2-(4'-carboxybutyl)-glycero-3 -phosphocholine.
  • l-hexadecyl-2-(4'-carboxy)butyl-glycero-3 -phosphocholine and 1- hexadecyl-2-(4'-carboxybutyl)-glycero-3 -phosphocholine are the same and both refer to the same compound, VB-201.
  • VB-201 may be a chiral enantiomer of l-hexadecyl-2-(4'-carboxybutyl)-glycero-3 -phosphocholine, i.e., either the (R)- enantiomer (( ?
  • the oxidized phospholipid is ( ? ) -l-hexadecyl-2-(4'-carboxy)butyl-5 «-glycero-3- phosphocholine.
  • the ( ? ) -l-hexadecyl-2-(4'-carboxy)butyl-5 «-glycero-3- phosphocholine.
  • -l-hexadecyl-2-(4'-carboxy)butyl-5 «- glycero-3 -phosphocholine has an enantiomeric purity of about 80% ee or more, e.g., about 85% ee, about 90% ee, about 91% ee, about 92% ee, about 93% ee, about 94% ee, about 95% ee, about 96% ee, about 97% ee, about 98% ee, about 99% ee, about 99.5% ee or more.
  • the ( ?) -l-hexadecyl-2-(4'-carboxy)butyl-5 «- glycero-3 -phosphocholine has an enantiomeric purity of about 80% ee or more, e.g., about 85% ee, about 90% ee, about 91% ee, about 92% ee, about 93% ee, about 94%
  • -l-hexadecyl-2-(4'-carboxy)butyl-5 «-glycero-3- phosphocholine has an enantiomeric purity of from about 80% ee to about 100% ee, about 85%) ee to about 100% ee, about 90% ee to about 100% ee, about 95% ee to about 100%, about 80% ee to about 99.5% ee, about 85% ee to about 99.5% ee, about 90% ee to about 99.5%) ee, about 95% ee to about 99.5%, or any range thereof.
  • the oxidized lipid has the following structure:
  • the oxidized lipid has the following structure:
  • an oxidized lipid compound of the invention treats or prevents fibrosis (e.g., liver fibrosis, kidney fibrosis, focal and segmental glomerulosclerosis, or any other fibrosis described herein) as well as, or better than, telmisartan.
  • fibrosis e.g., liver fibrosis, kidney fibrosis, focal and segmental glomerulosclerosis, or any other fibrosis described herein
  • an oxidized lipid compound of the invention reduces liver inflammation as well as, or better than, telmisartan.
  • an oxidized lipid compound of the invention reduces liver fibrosis as well as, or better than, telmisartan.
  • an oxidized lipid compound of the invention treats or prevents kidney fibrosis as well as, or better than, telmisartan.
  • an oxidized lipid compound of the invention treats or prevents focal and segmental glomerulosclerosis as well as, or better than,
  • compositions comprising an oxidized lipid of the invention.
  • the pharmaceutical composition comprises an oxidized lipid of the invention and a pharmaceutically acceptable vehicle.
  • the pharmaceutical composition comprises a therapeutically effective amount of the oxidized lipid.
  • the pharmaceutical composition comprises a therapeutically effective amount of the oxidized lipid and a pharmaceutically acceptable vehicle.
  • a therapeutically effective amount of an oxidized lipid is an amount effective to treat or prevent a disease or disorder of the present invention.
  • compositions of the present invention can be orally administered.
  • the pharmaceutical composition comprises a compound having a structure according to Formula 1 :
  • n is an integer from 1 to 6, wherein when n is 1, Cn, Bn, Rn, and Y are absent, and
  • Ci is attached to R'n;
  • each of Bi, B 2 , ...Bn-1 and Bn is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, wherein each of said nitrogen, phosphorus and silicon is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo;
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4, 5 -biphosphonate, phosphoinositol-4, 5 -bi sphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, phosphoglycerol and
  • each of B' and B" is independently selected from the group consisting of sulfur and oxygen;
  • each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate;
  • each of Xi, X 2 , ...Xn-1 is independently a saturated or unsaturated hydrocarbon having the general Formula 2:
  • n is an integer from 1 to 26;
  • W is selected from the group consisting of oxygen and sulfur
  • Rb, ...Rm-1, Rm-1, Rm and Rm is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aiyloxy, thiohydroxy, thioalkoxy, thioaiyloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O- carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of Ri, R'i, R2, ...Rn-1, Rn and R'n and/or at least two of Ra, R'a, Rb, R'b, ...Rm-1, R'
  • the pharmaceutical composition comprises a compound having a structure according to Formula 3 :
  • n is an integer selected from 1 to 4.
  • each B 2 , and B 3 are independently selected from the group consisting of oxygen, sulfur, and R 4 , wherein R 4 is selected from hydrogen, alkyl, cycloalkyl, aryl, and acyl.
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol, and a moiety having the general formula:
  • each of B and B a is independently selected from the group consisting of sulfur and oxygen;
  • D and D a are independently selected from the group consisting of hydrogen, alkyl, aminoalkyl, cycloalkyl, phosphonate and thiophosphonate.
  • Xi and each X 2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of Xi and X 2 is substituted with an oxidized moiety Z selected from the group consisting of:
  • W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
  • m is an integer selected from 1 to 26.
  • Z is selected from the group consisting of:
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaiyl,
  • Rc and Rc C are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, tnhalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C- carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, wherein at least two of Ri, Ria, R 2 , R 3 and R 3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring, and wherein at least two of R
  • n is 1 or 2. In another embodiment in Formula 3, n is 1 or 2.
  • n 1
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl
  • Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
  • Y is phosphoryl choline.
  • Z is ' .
  • Z is a carboxylic acid group.
  • n 1 and Y is phosphoryl choline.
  • each of Bi, B 2 , and B 3 is oxygen.
  • n is 1
  • Y is phosphoryl choline
  • Bi, B 2 , and B 3 is oxygen.
  • the pharmaceutical composition comprises a compound having a structure according to Formula 3a:
  • Bi, B 2 , and B 3 are independently selected from oxygen and sulfur.
  • a 1 and A 2 are independently selected from the group consisting of
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- di ethyl enetri amine-pentaacetate, dinitropheny 1 -pho sphoethanol amine, and phosphoglycerol.
  • Ri, Ri a , R 2 , R 3 , and R 3a are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S- thiocarboxy and amino, wherein at least two of Ri, Ri a , R 2 , R 3 and R 3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicycloalkyl,
  • Xi and X 2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of Xi and X 2 is substituted with an oxidized moiety Z having a formula selected from:
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
  • Xi and X 2 independently have a structure according to Formula 4a:
  • m is an integer selected from 1 to 26.
  • R a , Ra 3 ⁇ 4 each R , each R b , Rc, and Rc C are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C- thiocarboxy, S-thiocarboxy and amino, wherein at least two of R a , R aa , R b , R bb , Rc, and Rcc are optionally joined to form
  • Z is selected from the group consisting of:
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaiyl, wherein at least one of Xi and X 2 comprises a Z other than hydrogen.
  • Z is In another embodiment in Formula 3a, Z is In another embodiment in
  • Formula 3a Z is a carboxylic acid group.
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)] , phosphoinositol-4-phosphate, phosphoinositol-4, 5 -bi sphosphate, phosphoethanolamine-diethylenetriamine-pentacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
  • Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine.
  • Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
  • Y is phosphoryl choline.
  • each of Bi, B 2 , and B 3 is oxygen.
  • Y is phosphoryl choline, and each of Bi,
  • B 2 , and B 3 is oxygen.
  • the oxidized phospholipid has a structure according to Formula 4b:
  • each of Bi, B 2 , B 3 in Formula 4b is oxygen and the oxidized phospholipid has a structure according to the Formula 4c:
  • Ai in Formula 4c is CH 2 .
  • a 2 is absent or CH 2 .
  • Xi is an alkyl having from 1 to 30 carbon atoms.
  • E is absent or is an alkyl chain having from 1 to 24 carbon atoms
  • F is selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halide, acetoxy and aryl;
  • Z is selected from the group consisting of:
  • R is selected from H, alkyl and aryl.
  • Y is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N- [methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5- bisposphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentacetate, dinitrophenyl-phosphoethanolamine, phospho
  • X 1 is alkyl having from 10 to 30 carbon atoms, or from 8 to 30 carbon atoms.
  • E is alkyl having from 1 to 10 carbon atoms, or from 1 to 4 carbon atoms.
  • Y is phosphoryl choline.
  • Each carbon atom in Formula 1, 2, 3, 3a, 4b and 4c is a chiral or non-chiral carbon atom, wherein each chiral carbon atom can have S-configuration or R-configuration.
  • the pharmaceutical compositions of the invention comprise l-hexadecyl-2-(4'-carboxy)butyl-glycero-3-phosphocholine or l-hexadecyl-2- (4'-carboxybutyl)-glycero-3-phosphocholine (VB-201).
  • the pharmaceutical compositions of the invention comprise ( ? ) -l-hexadecyl-2-(4 l - carboxy)butyl-s «-glycero-3-phosphocholine.
  • the (K -l-hexadecyl- 2-(4'-carboxy)butyl-s «-glycero-3-phosphocholine has an enantiomeric purity of about 80% ee or more, e.g., about 85%> ee, about 90% ee, about 91% ee, about 92% ee, about 93% ee, about 94% ee, about 95% ee, about 96% ee, about 97% ee, about 98% ee, about 99%) ee, about 99.5% ee or more.
  • ) -l-hexadecyl-2-(4 l - carboxy)butyl-s «-glycero-3-phosphocholine has an enantiomeric purity of from about 80% ee to about 100% ee, about 85% ee to about 100% ee, about 90% ee to about 100% ee, about 95% ee to about 100%, about 80% ee to about 99.5% ee, about 85% ee to about 99.5% ee, about 90% ee to about 99.5% ee, about 95% ee to about 99.5%, or any range thereof.
  • compositions of the invention comprise a compound of the following structure:
  • compositions of the invention compri a compound of the following structure:
  • the pharmaceutical composition treats or prevents fibrosis
  • the pharmaceutical composition reduces liver inflammation as well as, or better than, telmisartan.
  • the pharmaceutical composition reduces liver fibrosis as well as, or better than, telmisartan.
  • the pharmaceutical composition treats or prevents kidney fibrosis as well as, or better than, telmisartan.
  • the pharmaceutical composition treats or prevents focal and segmental glomerulosclerosis as well as, or better than, telmisartan.
  • Embodiments of the invention relate to a method for treating or preventing fibrosis or liver inflammation comprising administering an oxidized lipid of the invention.
  • the method comprises administering a therapeutically effective amount of an oxidized lipid of the invention to a subject in need thereof.
  • the method comprises administering a pharmaceutical composition of the invention.
  • the fibrosis is pulmonary fibrosis, liver fibrosis, skin fibrosis, or kidney fibrosis.
  • the fibrosis is heart fibrosis, bone marrow fibrosis, intestine fibrosis, joint fibrosis (knee, shoulder, or other joints), hand fibrosis, finger fibrosis, skeletal muscle fibrosis, neurofibrosis, and penis fibrosis.
  • the fibrosis is idiopathic pulmonary fibrosis (IPF), cystic fibrosis, progressive massive fibrosis, cirrhosis, steatohepatitis (fatty liver disease), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), endomyocardial fibrosis, myocardial infarction, atrial fibrosis, medastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, nephrogenic systemic fibrosis, keloid, Crohn's disease, scleroderma/systemic sclerosis, arthrofibrosis, Peyronie's disease, Dupuytren's contracture, adhesive capsulitis, or focal and segmental glomerulosclerosis.
  • IPF idiopathic pulmonary fibrosis
  • cystic fibrosis progressive massive fibrosis
  • cirrhosis steatohepatitis (fatty
  • the fibrosis is associated with liver inflammation.
  • the fibrosis is liver fibrosis.
  • the fibrosis is kidney fibrosis.
  • the subject in need of treatment or prevention of kidney fibrosis has a chronic kidney disease.
  • the fibrosis is focal and segmental glomerulosclerosis.
  • the subject in need of treatment or prevention of focal and segmental glomerulosclerosis has a chronic kidney disease.
  • the fibrosis is a fibrosis that does not include idiopathic pulmonary fibrosis. In other embodiments, the fibrosis is a fibrosis that does not include cystic fibrosis. In other embodiments, the fibrosis is a fibrosis that does not include progressive massive fibrosis. In some embodiments, the fibrosis is a fibrosis that does not include cirrhosis. In some embodiments, the fibrosis is a fibrosis that does not include steatohepatitis (fatty liver disease). In some embodiments, the fibrosis is a fibrosis that does not include nonalcoholic fatty liver disease (NAFLD).
  • NAFLD nonalcoholic fatty liver disease
  • the fibrosis is a fibrosis that does not include nonalcoholic steatohepatitis (NASH).
  • NASH nonalcoholic steatohepatitis
  • the fibrosis is a fibrosis that does not include endomyocardial fibrosis.
  • the fibrosis is a fibrosis that does not include myocardial infarction.
  • the fibrosis is a fibrosis that does not include atrial fibrosis.
  • the fibrosis is a fibrosis that does not include medastinal fibrosis.
  • the fibrosis is a fibrosis that does not include myelofibrosis.
  • the fibrosis is a fibrosis that does not include retroperitoneal fibrosis. In some embodiments, the fibrosis is a fibrosis that does not include nephrogenic systemic fibrosis. In some embodiments, the fibrosis is a fibrosis that does not include keloid. In some embodiments, the fibrosis is a fibrosis that does not include Crohn's disease. In some embodiments, the fibrosis is a fibrosis that does not include scleroderma/systemic sclerosis. In some embodiments, the fibrosis is a fibrosis that does not include arthrofibrosis.
  • the fibrosis is a fibrosis that does not include Peyronie's disease. In some embodiments, the fibrosis is a fibrosis that does not include Dupuytren's contracture. In some embodiments, the fibrosis is a fibrosis that does not include adhesive capsulitis. In some embodiments, the fibrosis is a fibrosis that does not include focal and segmental glomerulosclerosis. In some embodiments, the fibrosis is a fibrosis that does not include fibrous lesions or plaques in the arteries.
  • the oxidized lipid treats or prevents liver inflammation, but does not alter liver fibrosis. In other embodiments, the oxidized lipid treats or prevents liver fibrosis, but does not alter liver inflammation.
  • activity of TLR2, TLR4 and/or CD14 is inhibited in a treated cell.
  • activity of TLR2 and TLR4 is inhibited; activity of TLR4 and CD14 is inhibited; activity of TLR2 and CD14 is inhibited; or activity of TLR2, TLR4 and CD14 is inhibited.
  • steatosis in a subject treated with an oxidized lipid of the invention is not reduced, compared to that in untreated or placebo-treated subjects.
  • liver lobular formation in a subject treated with an oxidized lipid of the invention is decreased, compared to that in untreated or placebo-treated subjects.
  • liver lobular formulation in a subject treated with an oxidized lipid of the invention is not decreased, compared to that in untreated or placebo-treated subjects.
  • steatosis in a subject treated with an oxidized lipid of the invention is not reduced and liver lobular formation in a subject treated with an oxidized lipid of the invention is decreased, compared to those in untreated or placebo-treated subjects, respectively.
  • steatosis in a subject treated with an oxidized lipid of the invention is not reduced and liver lobular formation in a subject treated with an oxidized lipid of the invention is not decreased, compared to those in untreated or placebo-treated subjects, respectively.
  • foam cell-like macrophages are decreased in a subject treated with an oxidized lipid of the invention, compared to that in untreated or placebo-treated subjects.
  • liver lobular formation and foam cell-like macrophages in a subject treated with an oxidized lipid of the invention are decreased, compared to those in untreated or placebo-treated subjects, respectively.
  • liver lobular inflammation in a subject treated with an oxidized lipid of the invention is decreased, compared to that in untreated or placebo-treated subjects.
  • liver lobular inflammation and foam cell-like macrophages in a subject treated with an oxidized lipid of the invention are decreased, compared to those in untreated or placebo- treated subjects, respectively.
  • liver lobular formation, liver lobular inflammation and foam cell-like macrophages in a subject treated with an oxidized lipid of the invention are decreased, compared to those in untreated or placebo- treated subjects, respectively.
  • liver lobular formation in a subject treated with an oxidized lipid of the invention is decreased by about 5% to about 50% (e.g., about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, or any ranges between the specified values) compared to that in untreated or placebo-treated subjects.
  • the formation of foam cell-like macrophages in a subject treated with an oxidized lipid of the invention is decreased by about 5% to about 50% (e.g., about 5%), about 10%), about 20%, about 30%, about 40%, about 50%, or any ranges between the specified values) compared to that in untreated or placebo-treated subjects.
  • liver lobular inflammation in a subject treated with an oxidized lipid of the invention is decreased by about 5% to about 50% (e.g., about 5%, about 10%, about 20%, about 30%), about 40%, about 50%, or any ranges between the specified values) compared to that in untreated or placebo-treated subjects.
  • the oxidized lipid is a compound having a structure according to Formula 1 :
  • n is an integer from 1 to 6, wherein when n is 1, Cn, Bn, Rn, and Y are absent, and
  • Ci is attached to R'n;
  • each of Bi, B 2 , ...Bn-1 and Bn is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, wherein each of said nitrogen, phosphorus and silicon is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo;
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4, 5 -biphosphonate, phosphoinositol-4, 5 -bi sphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, phosphoglycerol and
  • each of B' and B" is independently selected from the group consisting of sulfur and oxygen;
  • each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate;
  • each of Xi, X 2 , ...Xn-1 is independently a saturated or unsaturated hydrocarbon having the general Formula 2:
  • Z is selected from the group consisting of:
  • W is selected from the group consisting of oxygen and sulfur
  • Rb, ...Rm-1, R'm-l, Rm and Rm is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aiyloxy, thiohydroxy, thioalkoxy, thioaiyloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O- carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of Ri, R'i, R2, ...Rn-1, Rn and R'n and/or at least two of Ra, R'a, Rb, R'b, ...Rm-1,
  • the oxidized lipid is a compound having a structure according to Formula 3 :
  • n is an integer selected from 1 to 4.
  • each B 2 , and B 3 are independently selected from the group consisting of oxygen, sulfur, and R 4 , wherein R 4 is selected from hydrogen, alkyl, cycloalkyl, aryl, and acyl.
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol, and a moiety having the general formula:
  • each of B and B a is independently selected from the group consisting of sulfur and oxygen;
  • D and D a are independently selected from the group consisting of hydrogen, alkyl, aminoalkyl, cycloalkyl, phosphonate and thiophosphonate.
  • Xi and each X 2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of Xi and X 2 is substituted with an oxidized moiety Z selected from the group consisting of:
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
  • m is an integer selected from 1 to 26.
  • Z is selected from the group consisting of:
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaiyl,
  • Rc and Rc C are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, tnhalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C- carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, wherein at least two of Ri, Ria, R 2 , R 3 and R 3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring, and wherein at least two of R
  • n is 1 or 2. In another embodiment in Formula 3, n is 1 or 2.
  • n 1
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
  • Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine. [0325] In another embodiment in Formula 3, Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
  • Y is phosphoryl choline.
  • Z is .
  • Z is a carboxylic acid group.
  • n 1 and Y is phosphoryl choline.
  • each of Bi, B 2 , and B 3 is oxygen.
  • n is 1
  • Y is phosphoryl choline
  • Bi, B 2 , and B 3 is oxygen.
  • the oxidized lipid has a structure according to Formula 3a:
  • Bi, B 2 , and B 3 are independently selected from oxygen and sulfur.
  • a 1 and A 2 are independently selected from the group consisting of
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- di ethyl enetri amine-pentaacetate, dinitropheny 1 -pho sphoethanol amine, and phosphoglycerol.
  • Ri, Ri a , R 2 , R 3 , and R 3a are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S- thiocarboxy and amino, wherein at least two of Ri, Ri a , R 2 , R 3 and R 3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic
  • X 1 and X 2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of X 1 and X 2 is substituted with an oxidized moiety Z having a formula selected from:
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
  • X 1 and X 2 independently have a structure according to Formula 4a:
  • Formula 4a [0340]
  • m is an integer selected from 1 to 26.
  • R a , Raa, each R b , each R bb , R ⁇ , and Rc C are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C- thiocarboxy, S-thiocarboxy and amino, wherein at least two of R a , R aa , R b , 3 ⁇ 4 b , Rc, and Rcc are optionally
  • Z is selected from the group consisting of:
  • W is oxygen or sulfur; and R d and R dd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaiyl, wherein at least one of Xi and X 2 comprises a Z other than hydrogen.
  • Z is x .
  • Formula 3a Z is a carboxylic acid group.
  • Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)] , phosphoinositol-4-phosphate, phosphoinositol-4, 5 -bi sphosphate, phosphoethanolamine-diethylenetriamine-pentacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
  • Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine.
  • Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
  • Y is phosphoryl choline.
  • each of Bi, B 2 , and B 3 is oxygen.
  • Y is phosphoryl choline, and each of Bi,
  • B 2 , and B 3 is oxygen.
  • the oxidized phospholipid has a structure according to Formula 4b:
  • each of Bi, B 2 , B 3 in Formula 4b is oxygen and the oxidized phospholipid has a structure according to the Formula 4c:
  • a 1 in Formula 4c is CH 2 .
  • a 2 is absent or CH 2 .
  • X 1 is an alkyl having from 1 to 30 carbon atoms.
  • E is absent or is an alkyl chain having from 1 to 24 carbon atoms
  • F is selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halide, acetoxy and aryl;
  • Z is selected from the group consisting of:
  • R d is selected from H, alkyl and aryl.
  • Y is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N- [methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5- bisposphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentacetate, dinitrophenyl-phosphoethanolamine, and
  • X 1 is alkyl having from 10 to 30 carbon atoms, or from 8 to 30 carbon atoms.
  • E is alkyl having from 1 to 10 carbon atoms, or from 1 to 4 carbon atoms.
  • Y is phosphoryl choline.
  • Each carbon atom in Formula 1, 2, 3, 3a, 4b, and 4c is a chiral or non-chiral carbon atom, wherein each chiral carbon atom can have S-configuration or R- configuration.
  • the oxidized lipid is l-hexadecyl-2-(4'-carboxy)butyl- glycero-3 -phosphocholine or 1 -hexadecyl-2-(4'-carboxybutyl)-glycero-3 -phosphocholine (VB-201).
  • the oxidized lipid is 7 ⁇ ) -l-hexadecyl-2-(4'- carboxy)butyl-s «-glycero-3 -phosphocholine.
  • the K -l-hexadecyl- 2-(4'-carboxy)butyl-s «-glycero-3 -phosphocholine has an enantiomeric purity of about 80% ee or more, e.g., about 85%> ee, about 90%> ee, about 91%> ee, about 92%> ee, about 93% ee, about 94% ee, about 95% ee, about 96% ee, about 97% ee, about 98% ee, about 99%) ee, about 99.5%> ee or more.
  • -l-hexadecyl-2-(4 l - carboxy)butyl-s «-glycero-3 -phosphocholine has an enantiomeric purity of from about 80% ee to about 100% ee, about 85% ee to about 100% ee, about 90% ee to about 100% ee, about 95%> ee to about 100%>, about 80%> ee to about 99.5%> ee, about 85%> ee to about 99.5% ee, about 90% ee to about 99.5% ee, about 95% ee to about 99.5%, or any range thereof.
  • the oxidized lipid has the following structure:
  • the oxidized lipid has the following structure:
  • the oxidized lipid compound treats or prevents fibrosis
  • the oxidized lipid compound reduces liver inflammation as well as, or better than, telmisartan.
  • the oxidized lipid compound reduces liver fibrosis as well as, or better than, telmisartan.
  • the oxidized lipid compound treats or prevents kidney fibrosis as well as, or better than, telmisartan.
  • the oxidized lipid compound treats or prevents focal and segmental glomerulosclerosis as well as, or better than, telmisartan.
  • the subject is a mammal or a human.
  • the human is a female.
  • the human is a male.
  • VB-201 Inhibits LPS (TL 4)-Induced Signaling in Human monocytes (primary
  • PBMCs were isolated on Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) using 50 ml Leucosep tubes (Greiner Bio-One, Frickenhausen, Germany). Cells were washed in PBS (Kibbutz Beit Haemek, Israel) and incubated at 4 °C for 15 minutes in a buffer containing PBS and 0.5% bovine serum albumin (BSA) with human CD 14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).
  • BSA bovine serum albumin
  • FIG. 1 or with solvent (Sol), followed by 15 min activation with 100 ng/ml lipopolysaccharide (LPS) or were untreated (Unt).
  • LPS lipopolysaccharide
  • Unt untreated
  • Cells were washed and resuspended in lysis buffer containing 1 : 100 dithiothreitol (DTT), phosphatase and protease inhibitors (Thermo Scientific). Samples were loaded onto a precast Criterion TGX gel (Bio-Rad, Hemel Hempstead, UK) and transferred onto nitrocellulose membrane. Blots were blocked with 5% milk or BSA in Tris buffered saline and Tween 20 (TBST) for 1 h, followed by incubation with primary and secondary antibodies.
  • Membranes were developed using an ECL kit (Thermo Scientific). The following antibodies were used for immunoblotting:
  • Protein 90 (HSP90) served as a loading control.
  • VB-201 inhibits formation of p-IKK, p- ERK and p-p38 and p-AKT induced by LPS in human monocytes in a dose dependent manner. Accordingly, VB-201 inhibits LPS (TLR4)-induced signaling.
  • VB-201 Inhibits PGN (TLR2)-Induced Signaling in human monocytes (THP-1 cell line)
  • the monocytic TFIP-1 cell line was purchased from the American Type Tissue
  • p-ERKl/2 (Cat. No. M8159; 1 : 10000) was purchased from Sigma (Israel). aTubulin served as a loading control.
  • THP-1 cells were treated and analyzed by western blot.
  • Figures 2A-2B show that
  • VB-201 inhibits formation of p-IKK, p-ERK and p-p38 induced by PGN in THP-1 cells. Accordingly, VB-201 inhibits PGN (TLR2)-induced signaling.
  • VB-201 Inhibits MCP-1 -Induced Signaling in human monocytes (THP-1 cell line)
  • THP-1 cells (10 6 /ml) were pretreated for 20 min with VB-201 at the doses indicated in Figure 4, or with solvent, followed by activation with 50 ng/ml MCPl, or were untreated ("Unt"). Cells were washed and resuspended in lysis buffer containing 1 : 100 dithiothreitol (DTT), phosphatase and protease inhibitors (Thermo Scientific). Samples were loaded onto a precast Criterion TGX gel (Bio-Rad, Hemel Hempstead, UK) and transferred onto nitrocellulose membrane.
  • DTT dithiothreitol
  • phosphatase and protease inhibitors Thermo Scientific
  • p-AKT (Cat. No. 4060; 1 : 1000) was purchased from Cell Signaling Technology (Danvers, MA). aTubulin served as a loading control and was purchased from Sigma (Israel).
  • Figure 3 shows that VB-201 inhibits formation of p-AKT and p-ERK induced by
  • PBMCs were isolated on Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) using 50 ml Leucosep tubes (Greiner Bio-One, Frickenhausen, Germany). Cells were washed in PBS (Kibbutz Beit Haemek, Israel) and incubated at 4 °C for 15 minutes in a buffer containing PBS and 0.5% bovine serum albumin (BSA) with human CD 14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).
  • BSA bovine serum albumin
  • RANTES 100 ng/ml; Cat. No.
  • VB-201 Inhibits SDFl -Induced Migration in human monocytes (THP-1 cell line) Methods and Materials
  • THP-1 cells (10 6 /ml) were pretreated for 20 min with VB-201 or with solvent
  • RANTES 100 ng/ml, Cat. No. 300- 06
  • MCP-1 50 ng/ml, Cat. No. 300-04
  • FBS fetal bovine serum
  • Figure 5 shows VB-201 inhibits SDFl -induced migration of human monocytes
  • THP-1 cell line THP-1 cell line
  • VB-201 Inhibits RANTES-Induced Signaling in human monocytes (primary
  • VB-201 Inhibits IL-12p40 Levels in human monocytes (primary CD 14+), stimulated by LPS (via TL 4) or Pam3CSK4 (via TLR2)
  • Human monocytes were seeded (10 6 /ml) and pretreated for 1 hour with VB-201, followed by 24 hour activation with 100 ng/ml LPS from Escherichia coli strain 055:B5 (Sigma, Israel) ( Figure 7A) or 300 ng/ml Pam3CSK4 (InvivoGen, San Diego, CA, USA) ( Figure 7B) to induce cytokine production.
  • IL-12/23p40 concentration in the supernatant was then measured by ELISA (R&D systems, Cat. No. DY1240).
  • Cells activated with solvent (0.5% ethanol in PBS) were used as a control.
  • FIGS 7A-7B show that VB-201 inhibits secretion of IL-12p40 by LPS (TLR4)- stimulated and Pam3CSK4 (TLR2)-stimulated human monocytes (primary CD14+).
  • PBMCs were isolated on Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) using 50 ml Leucosep tubes (Greiner Bio-One, Frickenhausen, Germany). Cells were washed in PBS (Kibbutz Beit Haemek, Israel) and incubated at 4 °C for 15 minutes in a buffer containing PBS and 0.5% bovine serum albumin (BSA) with human CD 14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).
  • BSA bovine serum albumin
  • VB-201 were incubated for 20 min with cells (10 6 /ml) after which 100 ng/ml of biotin-LPS (InvivoGen) was added for an additional 15 minutes, all at 4 °C. Cells were washed, resuspended in FACS buffer and analyzed on a FACS-Calibur device.
  • biotin-LPS InvivoGen
  • Figure 8 shows that VB-201 inhibited the binding to human monocytes (primary
  • CD14+ of LPS with an IC50 of ⁇ 7 ⁇ g/ml.
  • VB-201 Inhibits IL-6 Secretion in LPS (LLR4)- Stimulated Monocyte-Derived Dendritic Cells (Mo-Derived DCs)
  • CD14+ monocytes were counted, washed and seeded (10 6 /ml) in medium containing RPMI-1640, L-glutamine, ⁇ - mercaptoethanol, 10% fetal calf serum (FCS), sodium pyruvate, non-essential amino acids, 0.01 M HEPES, antibiotics (penicillin, streptomycin), 50 ng/ml human granulocyte-macrophage colony-stimulating factor (GMCSF) and 20 ng/ml human IL-4 (both from PeproTech Asia, Israel). Medium was replaced every 2-3 days.
  • Mo-DCs were collected 5-6 days post-culture, counted and seeded (10 6 /ml). Cells were pretreated for 1 hour with VB-201, followed by 24 hours activation with 100 ng/ml LPS from Escherichia coli strain 055 :B5 (Sigma, Israel) to induce cytokine production. IL-6 concentration ( Figure 9) in supernatant was measured by ELISA (R&D systems, Cat. No. DY206). Cells activated with solvent (0.5% ethanol in PBS) were used as a control.
  • FIG. 9 shows VB-201 inhibits IL-6 secretion in LPS (TLR4) stimulated Mo-
  • VB-201 Inhibits IL-12p40 Secretion in LPS (TLR4) Stimulated Mo-Derived DCs
  • FIG. 10 shows VB-201 inhibits IL-12p40 secretion in LPS (TLR4) stimulated Mo-Derived DCs.
  • NASH nonalcoholic steatohepatitis
  • NASH was induced in 40 male mice by a single subcutaneous injection of 200 ⁇ g per mouse of STZ two days after birth and feeding HFD [57 kcal% fat]) from four weeks of age.
  • liver pathology was used to determine the effect of VB-201 on liver inflammation and fibrosis. Histology slides were stained with hematoxylin/eosin (H&E) to assess inflammation. The inflammation score was determined as follows:
  • FIGS 11A-11B show that disease induction resulted in notable inflammation in the liver of vehicle treated mice.
  • Treatment with VB-201 significantly curtailed inflammation by 65%.
  • Administration with the positive control telmisartan significantly reduced liver inflammation by 77%.
  • Figures 12A-12B show that disease induction in Example 11 also resulted in notable increases in the fibrosis area in the liver of vehicle treated mice.
  • the results in Figures 12A-12B demonstrate that VB-201 significantly decreased the extent of fibrosis (by about 34%) compared to the vehicle treated mice.
  • Chronic renal failure was induced by a two stage (5/6) nephrectomy (Nx), with subtraction firstly of about 2/3 of the left kidney by left flank incision and, one week later, complete removal of the right kidney.
  • Nx nephrectomy
  • General anesthesia consisted of intraperitoneal injection of ketamine 100 mg/kg and xylazine 20 mg/kg (0.85 ml ketamine + 0.15 ml xylazine for each ml preparation; 1 ⁇ /g BW was injected LP).
  • Nephrectomized, orally administered with VB-201 4 mg/kg (n 8);
  • BW Body weight
  • kidneys were collected, weighed and fixed in 4% formaldehyde.
  • Periodic Acid-Schiff (PAS) reagent Periodic Acid-Schiff
  • Glomerular area The glomerular area of mostly 100 randomly selected glomeruli at a magnification of xlOO was quantitated by counting squares covered by glomeruli area using a grid and the mean glomeruli area was calculated.
  • Kidney RNA was extracted with an RNeasy Fibrous Tissue Mini kit (Qiagen) and after DNAse I treatment, single-stranded cDNA was synthesized from 2 ⁇ g total RNA using the qScript cDNA Synthesis Kit (Quanta Biosciences) and diluted for real-time PCR.
  • the expression of collagen 4a, fibronectin and TGFp was quantified using the 7300 Real Time PCR System (Applied Biosystems).
  • the assay was performed according to manufacturer instructions using the primers (Assay ID) represented at the table below supplied by Applied Biosystems. Data were normalized to the reference gene TATA-box Binding Protein (TBP) and presented as relative mRNA levels compared with Sham PBS 0.5% Eth treatment (Table 1).
  • Glomeruli were evaluated for their fibrosis extent by scoring and by calculation of the percent of glomeruli having segmental sclerosis, global sclerosis and the sum of global and segmental sclerotic glomeruli. Moreover, the area of the glomeruli was calculated and the percent of hypertrophied glomeruli was calculated. Damaged glomeruli included hypertrophied (at least xl .5 from normal area) and or sclerotic glomeruli. [0418] VB-201 and telmisartan treatment significantly reduced the damaged glomeruli by
  • FIG. 15 shows typical sclerotic changes in glomeruli (PAS staining) of vehicle treated nephrectomized animals in contrast with healthy or sham operated animals or with VB-201 treated animals or telmisartan treated animals.
  • TGF- ⁇ The mRNA expression of TGF- ⁇ was increased significantly by 10 or 8 fold, respectively, in vehicle treated nephrectomized rats (8.4 ⁇ 0.49), in contrast with healthy (0.9 ⁇ 0.24) or sham operated animals (l .OtO.23) (p ⁇ 0.001).
  • VB-201 and telmisartan treatment significantly (p ⁇ 0.001) reduced TGF- ⁇ expression by 37% (5.3 ⁇ 0.33) and 44% (4.7 ⁇ 0.52), respectively, compared to those observed for Nx PBS 0.5% Eth treatment (FIG. 17B).
  • RNeasy mini kit Qiagen
  • Q-PCR was performed with sets of probe with primer for mouse IL-12/23p40 (Applied Biosystems).
  • GAPDH was used to normalize RNA levels.
  • FIG. 18 shows that VB-201 inhibits IL-12/23p40 expression in livers of NASH- induced mice. Analysis of IL-12/23p40 in the livers of NASH-induced mice shows that VB-201 significantly attenuated the expression of IL-12/23p40.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to methods of treating or preventing fibrosis comprising an oxidized lipid or pharmaceutical composition comprising the same. In some embodiments, the present invention provides methods of treating or preventing fibrosis (e.g., liver fibrosis, kidney fibrosis, focal and segmental glomerulosclerosis, or any other fibrosis described herein), comprising administering to a subject in need thereof a therapeutically effective amount of a compound having a structure according to Formula 1.

Description

OXIDIZED LIPIDS AND TREATMENT OR PREVENTION OF FIBROSIS CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority benefit to U.S. Provisional Appl. No. 62/085,051 filed November 26, 2014, the contents of which are hereby incorporated by reference in their entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to methods of treating or preventing fibrosis with oxidized lipid compounds and pharmaceutical compositions comprising the same.
BACKGROUND OF THE INVENTION
[0003] Fibrosis is the formation of excess fibrous connective tissue in an organ or tissue.
Fibrosis encompasses the pathological state of excess deposition of fibrous tissue, as well as the process of connective tissue deposition in healing. Fibrosis is similar to the process of scarring, in that both involve stimulated cells (e.g., fibroblasts) laying down connective tissue, including collagen and glycosaminoglycans.
[0004] Fibrosis can be considered as a scarring process in response to chronic diseases where excessive extracellular matrix (ECM) deposition leads to irreversible tissue damage and failure or disturbance of proper organ function. The pathophysiology of fibrosis has generally been studied in the context of the particular organ or tissue affected, including lung, kidney, liver, heart and skin. Loss of metabolic homeostasis and chronic low-grade inflammation may play a role in the pathogenesis of fibrosis. Fibrogenesis is a dynamic process and occurs in four phases: i) initiation, due to injury of the organ/tissue; ii) inflammation and activation of effector cells; iii) enhanced synthesis of ECM; and iv) deposition of ECM with progression to end-organ failure.
[0005] Fibrosis can occur in many tissues within the body. Examples include pulmonary fibrosis (lungs), idiopathic pulmonary fibrosis (lungs), cystic fibrosis (lungs), progressive massive fibrosis (lungs), liver fibrosis, cirrhosis (liver), steatohepatitis (fatty liver disease), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), endomyocardial fibrosis (heart), myocardial infarction (heart), atrial fibrosis (heart), medastinal fibrosis (soft tissue of mediastinum), myelofibrosis (bone marrow), retroperitoneal fibrosis (soft tissue of the retroperitoneum), nephrogenic systemic fibrosis (skin), keloid (skin), Crohn's disease (intestine), scleroderma/systemic sclerosis (skin, lungs), arthrofibrosis (knee, shoulder, other joints), Peyronie's disease (penis), Dupuytren's contracture (hands, fingers), adhesive capsulitis (shoulder), kidney fibrosis, and focal and segmental glomerulosclerosis (kidney).
[0006] One of the major complications of insulin resistance and metabolic syndrome is nonalcoholic fatty liver disease (NAFLD), which can progress from fatty liver to liver inflammation (NASH) and liver fibrosis. It is believed that due to intestinal barrier leakage, accompanied by overgrowth and changes in the composition of gut flora, bacterial components travel through the portal vein into the liver, where they encounter toll-like receptors (TLRs).
[0007] TLRs are a family of receptors imperative for the innate immune response against microbial invasion. TLRs can be divided into two major subgroups based on their cellular localization. Plasma membrane expressed TLRs include TLR1, TLR2, TLR4, TLR5 and TLR6, whereas the intracellular TLRs include TLR3, TLR7, TLR8 and TLR9. The interaction between TLRs with their cognate agonists instigates a cascade of cues which include recruitment of the adaptor molecules MyD88/TRIF and downstream phosphorylation of MAPK kinases and NF-κΒ. These events culminate in the secretion of proinflammatory cytokines, including IL- 12/23, IL-6 and TNF-a. TLR2 forms a heterodimer with TLR1 which recognizes bacterial triacylated lipopeptides, and a heterodimer with TLR6 which recognizes bacterial diacylated lipopeptides. TLR4 coupled to MD2 in complex with lipopolysaccharide-binding protein (LBP) and the co- receptor CD 14 bind lipopoly saccharide (LPS) from gram negative bacteria.
[0008] Liver resident kupffer and hepatic stellate cells (HSC) express TLR2 which recognize triacylated lipopeptides from Gram-negative bacteria and mycoplasma and diacylated lipopeptides from Gram-negative bacteria and mycoplasma and TLR4 and its co-receptor CD14 which recognize lipopolysaccharide (LPS) from gram-negative bacteria. Both TLR2 and TLR4 can also bind to danger associated molecular patterns released from injured tissues. These TLR2 and TLR4 complexes mediate the production of pro-inflammatory cytokines and fibrogenic response by kupffer and stellate cells. Pre- clinical studies showed that nonalcoholic steatohepatitis and liver fibrosis are inhibited in TLR2 and TLR4 deficient mice, indicating its role in disease pathogenesis. In humans, LPS plasma levels are elevated in NAFLD patients and alterations in TLR4 and CD14 genes are associated with risks of developing nonalcoholic steatohepatitis and fibrogenesis.
[0009] Monocytes are key players in the immune system, with critical roles in innate and adaptive immunity, immune surveillance and particle scavenging. Whereas a subset of monocytes is "resident" and recruited to tissues independently of inflammatory stimuli to assist in steady-state surveillance, wound-healing and resolution of inflammation, the absolute majority (80-90%) of human circulating monocytes is classified as "inflammatory". These monocytes can sense inflammatory stimuli and quickly migrate through the vascular or lymphatic endothelium to the periphery, where they can differentiate into macrophages and dendritic cells (DCs) which cooperate with additional cell subsets (such as Thl-cells) to promote inflammation. While playing a necessary role in host defense, monocytes were nonetheless identified as critical mediators of several inflammatory diseases, including atherosclerosis, rheumatoid arthritis (RA) and multiple sclerosis (MS). Suppressing the accumulation of unwanted monocytes/macrophages in a chronically inflamed tissue has therapeutic potential, and migration inhibitors have accordingly demonstrated promising anti-inflammatory results in animal models and clinical trials.
[0010] Renal fibrosis (kidney fibrosis) is a wound healing/scarring response following kidney injury that occurs in many forms of chronic kidney disease (CKD). Following kidney injury, resident fibroblasts are activated by various pro-inflammatory and pro- fibrotic stimuli. Activated fibroblasts, also called myofibroblasts, produce excessive ECM proteins that accumulate in the interstitium, and therefore are considered a mediator of renal fibrosis. Regardless of the primary insult leading to renal fibrosis, chronic inflammation appears to be a process heralding renal fibrogenesis. Elevated levels of inflammatory markers were associated with an increased risk of developing CKD. Induction of various pro-inflammatory cytokines interleukin (IL)-6, IL-8, IL-10, chemokine (C-C motif) ligand 2 (CCL2), tumor necrosis factor-a (TNF-a) and adhesion molecules (intercellular adhesion molecule- 1 and vascular cell adhesion molecule- 1) attracted the transmigration of macrophages and T cells from the circulation to the interstitium, thereby further enhancing the inflammatory state. Evidence suggests that TLRs and macrophages are associated with the pathogenesis of renal fibrosis.
[0011] Fibrosis can cause severe morbidity and deleterious effects on patients' daily function, activity of daily living (ADL) and quality of life, and can lead to poor prognosis. For example, idiopathic pulmonary fibrosis ( PF) is a chronic intractable disease associated with worsening and debilitating shortness of breath. IPF patients become oxygen dependent, and have an average median survival time of three years and a five year survival rate of 20% to 40% after diagnosis. Therefore, the development of new therapies for fibrosis is needed.
SUMMARY OF THE INVENTION
In some embodiments, the present invention provides methods of treating or preventing fibrosis (e.g., liver fibrosis, kidney fibrosis, focal and segmental glomerulosclerosis, or any other fibrosis described herein), comprising administering to a subject in need thereof a therapeutically effective amount of a compound having a structure according to Formula 1 :
Formula 1
[0013] or a pharmaceutically acceptable salt, a hydrate or a solvate thereof,
[0014] wherein:
[0015] n is an integer from 1 to 6, wherein when n is 1, Cn, Bn, Rn, and Y are absent, and
Ci is attached to R'n; [0016] each of Bi, B2, ...Bn-1 and Bn is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, wherein each of said nitrogen, phosphorus and silicon is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy, and oxo;
[0017] each of Ai, A2, ...An-1 and An is independently selected from the group consisting of CR"R"', C=0 and C=S,
[0018] Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4, 5 -biphosphonate, phosphoinositol-4, 5 -bi sphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, phosphoglycerol and a moiety having the general formula:
[0019] wherein:
[0020] each of B' and B" is independently selected from the group consisting of sulfur and oxygen; and
[0021] each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate, and thiophosphonate; and
[0022] each of Xi, X2, ...Xn-1 is independently a saturated or unsaturated hydrocarbon having the general Formula 2: Ra Rb Rm-1 Rm
Ca Cb C m-1 Cm Z
R'a R'b R'm-1 R'm
Formula 2
[0023] wherein m is an integer from 1 to 26; and
[0024] Z is selected from the group consisting of:
R"
/ OR" WR"
R" w=c / /
w=c; W=
H, \ , ? , \ , WR- and -OR ,
[0025] wherein W is selected from the group consisting of oxygen and sulfur;
[0026] wherein at least one of Xi, X2, ...Xn-1 comprises a Z other than hydrogen,
[0027] and wherein:
[0028] each of Rb R'b R2, ... Rn-1, Rn, Rn, each of R" and R" and each of Ra, Ra, Rb,
Rb, ...Rm-1, R'm-1, Rm and Rm is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aiyloxy, thiohydroxy, thioalkoxy, thioaiyloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O- carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of Ri, R'i, R2, ...Rn-1, Rn and Rn and/or at least two of Ra, Ra, Rb, R'b, ...Rm-1, R'm-1, Rm and R'm form at least one four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring.
[0029] In some embodiments, the compound is l-hexadecyl-2-(4'-carboxybutyl)-glycero-
3-phosphocholine (VB-201). In some embodiments, the compound is (R)-l-hexadecyl-2- (4'-carboxybutyl)-sn-glycero-3-phosphocholine. In other embodiments, the compound has the following structure:
[0030] In other embodiments, the compound has the following structure:
BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention.
[0032] FIGs. 1A-1D show VB-201 inhibits lipopolysacchande (LPS) (TLR4)-induced signaling in human monocytes (primary CD 14+).
[0033] FIGs. 2A-2B show VB-201 inhibits PGN (TLR2)-induced signaling in human monocytes (THP-1 cell line). [0034] FIG. 3 shows VB-201 inhibits MCP-1 -induced signaling in human monocytes
(THP-1 cell line).
[0035] FIG. 4 shows VB-201 inhibits chemokine-induced migration of human monocytes
(primary CD 14+).
[0036] FIG. 5 shows VB-201 inhibits SDF1 -induced cell migration of human monocytes
(THP-1 cell line).
[0037] FIG. 6 shows VB-201 inhibits RANTES-induced signaling in human monocytes
(primary CD 14+).
[0038] FIGs. 7A-7B show VB-201 inhibits IL-12p40 levels in human monocytes
(primary CD14+) that are LPS (TLR4)-stimulated (FIG. 7A) and Pam3CSK4 (Unstimulated (FIG. 7B).
[0039] FIG. 8 shows the effect of VB-201 on LPS-binding by human primary monocytes.
Samples were incubated with VB-201 at the indicated concentrations for 20 minutes before biotin-LPS (100 ng/ml) was added for an additional 15 minutes. Results are the mean fluorescence intensity (MFI) of triplicates.
[0040] FIG. 9 shows VB-201 inhibits IL-6 secretion in LPS (TLR4)-stimulated human monocytes derived dendritic cells (Mo-derived DCs).
[0041] FIG. 10 shows VB-201 inhibits IL-12p40 secretion in LPS (TLR4)-stimulated human Mo-derived DCs.
[0042] FIGs. 11A-11B show the effect of VB-201 on liver inflammation (FIG. 11 A).
NASH was induced by injection of mice with 200 μg streptozotocin (STZ) two days after birth and by feeding a high fat diet (HFD) from four weeks of age. Mice were then either treated with vehicle (negative control), VB-201 (4 mg/kg), or telmisartan (10 mg/kg; positive control) at six weeks of age for three weeks, or not treated (Normal). Mice were sacrificed at nine weeks of age. FIG. 11A shows the mean liver inflammation score following treatment (Mean ± S.E; Normal - n=5, Vehicle - n=8, VB-201 - n=8, Telmisartan - n=6). FIG. 11B shows H&E stained liver samples following treatment (200X magnification).
[0043] FIGs. 12A-12B show the effect of VB-201 on liver fibrosis. NASH was induced as explained in FIGs. 1 lA-1 IB. Staining of liver histological samples with Sirius red was used to determine the extent of fibrosis. FIG. 12A shows the mean fibrosis area following treatment (% from analyzed liver section; Mean ± S.E; Normal - n=5, Vehicle - n=8, VB-201 - n=8, Telmisartan - n=6). FIG. 12B shows Sirius red staining of liver samples following treatment (200X magnification).
[0044] FIG. 13 presents bar graphs showing the effect of VB-201 in reducing the number of damaged glomeruli (%) in a renal fibrosis model. Damaged glomeruli (%) in healthy rats (n=3) (white bar), sham operated rats (n=3) (white bar with stripes), nephrectomized rats treated with solvent control (0.5% ethanol/PBS) (black bar) (n=7), nephrectomized rats VB-201 4 mg/kg treated (n=7) (light gray bar) or nephrectomized rats telmisartan 10 mg/kg treated (n=8) (dark gray bar) were evaluated at 8 weeks. Statistical data vs. nephrectomized rats treated with solvent control (0.5% ethanol/PBS) is presented as follows: * represents p=0.01; ** represents p<0.005; and *** represents p<0.001. Abbreviations are: Nx, nephrectomized; Eth, ethanol.
[0045] FIG. 14 presents bar graphs showing the effect of VB-201 in reducing glomerular sclerosis (%). Glomerular sclerosis (%) in healthy rats (n=3) (white bar), sham operated rats (n=3) (white bar with stripes), nephrectomized rats treated with solvent control (0.5% ethanol/PBS) (black bar) (n=7), nephrectomized rats VB-201 4 mg/kg treated (n=8) (light gray bar) or nephrectomized rats telmisartan 10 mg/kg treated (n=8) (dark gray bar) were evaluated at 8 weeks. Statistical data vs. nephrectomized rats treated with solvent control (0.5%) ethanol/PBS) is presented as follows: * represents p<0.05; ** represents p<0.005; and *** represents p<0.001. Abbreviations are: Nx, nephrectomized; Eth, ethanol.
[0046] FIG. 15 presents PAS staining (x400) images showing the effect of VB-201 in reducing glomerular sclerosis. Renal morphology was assessed by light microscope in PAS stained sections of healthy rats (Healthy x400), sham operated rats (Sham x400), nephrectomized rats treated with solvent control (0.5% ethanol/PBS) (Nx PBS 0.5% Eth x400), nephrectomized rats VB-201 4 mg/kg treated (Nx VB-201 4 mg/kg x400) or nephrectomized rats telmisartan 10 mg/kg treated (Nx Telmisartan 10 mg/kg x400) at 8 weeks following the first surgery. Abbreviations are: Nx, nephrectomized; Eth, ethanol, PAS, Periodic Acid-Schiff.
[0047] FIGs. 16A-16C show the effect of VB-201 on monocyte/macrophage cell infiltration in the glomeruli (FIG. 16A) or in the interstitium (FIG. 16B). CD68 positive cells in the glomeruli (cells/glomeruli) and in the interstitium (cells/mm2) were evaluated in healthy rats (n=3) (white bar), sham operated rats (n=3) (white bar with stripes), nephrectomized rats treated with solvent control (0.5%> ethanol/PBS) (black bar) (n=7), nephrectomized rats VB-201 4 mg/kg treated (n=8) (light gray bar) or nephrectomized rats telmisartan 10 mg/kg treated (n=8) (dark gray bar) were evaluated at 8 weeks. Statistical data vs. nephrectomized rats treated with solvent control (0.5% ethanol/PBS) is presented as follows: in FIG. 16A, * represents p=0.008; and ** represents p<0.001; and in FIG. 16B, * represents p<0.005. FIG. 16C presents representative CD68 staining (x400) images showing the effect of VB-201 in reducing the number of CD68 cells. Abbreviations are: Nx, nephrectomized; Eth, ethanol.
[0048] FIGs. 17A-17B present bar graphs showing the effect of VB-201 on pro-fibrotic markers. Relative expression of Collagen IV (FIG. 17A) and TGF-β (FIG. 17B) in the kidney was evaluated in healthy rats (white bar), sham operated rats (white bar with stripes), nephrectomized rats treated with solvent control (0.5% ethanol/PBS) (black bar), nephrectomized rats VB-201 4 mg/kg treated (light gray bar) or nephrectomized rats telmisartan 10 mg/kg treated (dark gray bar) at 8 weeks. Statistical data vs. nephrectomized rats treated with solvent control (0.5% ethanol/PBS) is presented as follows: in FIG. 17A, * represents p<0.05; and in FIG. 17B, * represents p<0.001. Abbreviations are: Nx, nephrectomized; Eth, ethanol.
[0049] FIG. 18 presents bar graphs showing that VB-201 inhibits IL-12/23p40 expression in livers of NASH-induced mice. Mice were induced for NASH and VB-201 was administered orally at a dose of 4 mg/kg once daily from Week 6 to Week 9. Telmisartan was administered at a dose of 10 mg/kg once daily. Q-PCR was performed on RNA extracted from livers of NASH-induced mice treated with vehicle (solvent, n=8), VB-201 (n=7), telmisartan (n=5) as described above, or from livers of normal mice. Q-PCR was used to detect IL-12/23p40. GAPDH was used to normalize RNA levels. Analysis of IL- 12/23p40 in the livers of NASH-induced mice shows that VB-201 significantly attenuated the expression of IL- 12/23 p40, with p < 0.05.
DETAILED DESCRIPTION OF THE INVENTION
[0050] Before explaining embodiments of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
General Definitions
[0051] The terms "comprises", "comprising", "includes", "including", "having", and their conjugates mean "including but not limited to."
[0052] The word "optionally" is used herein to mean "is provided in some embodiments and not provided in other embodiments." Any particular embodiment of the invention can include a plurality of "optional" features unless such features conflict.
[0053] As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
[0054] As used herein, the term "about" modifying an amount related to the invention refers to variation in the numerical quantity that can occur, for example, through routine testing and handling; through inadvertent error in such testing and handling; through differences in the manufacture, source, or purity of ingredients employed in the invention; and the like. Whether or not modified by the term "about", the claims include equivalents of the recited quantities. In one embodiment, the term "about" means within 10% of the reported numerical value.
[0055] The term "therapeutically effective amount," as used herein, refers to that amount of a given therapeutic agent sufficient to result in amelioration of one or more symptoms of a disorder or condition, or prevent appearance or advancement of a disorder or condition, or cause regression of or cure from the disorder or condition. In some embodiments, a therapeutically effective amount of VB-201 is about 5 mg to about 160 mg VB-201 per day.
[0056] As used herein throughout, the term "alkyl" refers to a saturated aliphatic hydrocarbon including straight chain and branched chain groups. In some embodiments, the alkyl group has 1 to 20 carbon atoms. Whenever a numerical range; e.g., " 1-20", is stated herein, it implies that the group, in this case the alkyl group, may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms. In some embodiments, the alkyl is a medium size alkyl having 1 to 10 carbon atoms. In some embodiments, the alkyl is a lower alkyl having 1 to 4 carbon atoms. The alkyl group can be substituted (e.g., with 1 to 5 substituent groups) or unsubstituted. In any of the embodiments described herein, the alkyl can be unsubstituted. In any of the embodiments described herein, the alkyl can also be substituted by one to five substituent groups, wherein the substituent group can be, for example, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, sulfonyl, sulfinyl, sulfonamide, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N- carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, and amino, as these terms are defined herein.
[0057] A "cycloalkyl" group refers to an all-carbon monocyclic or fused ring (i.e., rings which share an adjacent pair of carbon atoms) group wherein one of more of the rings does not have a completely conjugated pi-electron system. Examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, cycloheptane, cycloheptatriene, and adamantane. A cycloalkyl group can be substituted (e.g., with 1 to 5 substituent groups) or unsubstituted. In any of the embodiments described herein, the cycloalkyl can be unsubstituted. In any of the embodiments described herein, the cycloalkyl can also be substituted by one to five substituent groups, wherein the substituent group can be, for example, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, sulfonyl, sulfinyl, sulfonamide, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O- carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, and amino, as these terms are defined herein.
[0058] An "alkenyl" group refers to an aliphatic hydrocarbon group which contains at least two carbon atoms and at least one carbon-carbon double bond, which can be straight or branched. An alkenyl group can be substituted or unsubstituted.
[0059] An "alkynyl" group refers to an aliphatic hydrocarbon group which contains at least two carbon atoms and at least one carbon-carbon triple bond. An alkynyl group can be substituted or unsubstituted.
[0060] An "aryl" group refers to an all-carbon monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of carbon atoms) groups having a completely conjugated pi-electron system. In any of the embodiments described herein, aryl groups can have 6 to 14 carbons, e.g., 6 tolO carbons. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl. The aryl group can be substituted (e.g., with 1 to 5 substituent groups) or unsubstituted. When substituted, the substituent group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, sulfonyl, sulfinyl, sulfonamide, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, and amino, as these terms are defined herein. In any of the embodiments described herein, the aryl group can be a phenyl group, optionally substituted, for example, by one to five substituent such as halogens (e.g., fluorine or chlorine), alkyl groups (e.g., a C1-4 alkyl), or halogen substituted alkyls (e.g., trifluoromethyl).
[0061] A "heteroaryl" group refers to a monocyclic or fused ring (i.e., rings which share an adjacent pair of atoms) group having in the ring(s) one or more atoms, such as, for example, nitrogen, oxygen and sulfur and, in addition, having a completely conjugated pi- electron system. In any of the embodiments described herein, heteroaryl groups can have 5 to 14 ring atoms, e.g., 5 to 10 ring atoms (e.g., 5 or 6 ring atoms). Examples, without limitation, of heteroaryl groups include pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline and purine. The heteroaryl group can be substituted (e.g., with 1 to 5 substituent groups) or unsubstituted. When substituted, the substituent group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, sulfonyl, sulfinyl, sulfonamide, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O- carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, and amino, as these terms are defined herein.
[0062] A "heteroalicyclic" group refers to a monocyclic or fused ring group having in the ring(s) one or more heteroatoms such as nitrogen, oxygen and sulfur. The rings may also have one or more double bonds. However, the rings do not have a completely conjugated pi-electron system. In any of the embodiments described herein, heteroalicyclic groups can have 3 to 10 ring atoms, e.g., 5 to 10 ring atoms (e.g., 5 or 6 ring atoms). The heteroalicyclic can be substituted (e.g., with 1 to 5 substituent groups) or unsubstituted. When substituted, the substituted group can be, for example, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, heteroalicyclic, halo, hydroxy, alkoxy, aiyloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, cyano, nitro, azide, sulfonyl, sulfinyl, sulfonamide, phosphonyl, phosphinyl, oxo, carbonyl, thiocarbonyl, urea, thiourea, O- carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, and amino, as these terms are defined herein. Representative examples are piperidine, piperazine, tetrahydrofuran, tetrahydropyran, morpholine and the like.
[0063] An "alkoxy" group refers to both an -O-alkyl and an -O-cycloalkyl group, wherein the alkyl or cycloalkyl can be any of those as defined herein.
[0064] An "aiyloxy" group refers to both an -O-aiyl and an -O-heteroaiyl group, wherein the aryl or heteroaiyl can be any of those as defined herein.
[0065] A "thiohydroxy" group refers to a -SH group.
[0066] A "thioalkoxy" group refers to both an -S-alkyl group, and an -S-cycloalkyl group, wherein the alkyl or cycloalkyl can be any of those as defined herein.
[0067] A "thioaryloxy" group refers to both an -S-aryl and an -S-heteroaryl group, wherein the aryl or heteroaiyl can be any of those as defined herein.
[0068] A "carbonyl" group refers to a -C(=0)-R group, wherein R is hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heteroaiyl (bonded through a ring carbon) or heteroalicyclic
(bonded through a ring carbon) as defined herein.
[0069] An "aldehyde" group refers to a carbonyl group, wherein R is hydrogen.
[0070] A "thiocarbonyl" group refers to a -C(=S)-R group, wherein R is as defined herein.
[0071] A "C-carboxy" group refers to a -C(=0)-0-R groups, wherein R is as defined herein.
[0072] An "O-carboxy" group refers to an RC(=0)-0- group, wherein R is as defined herein.
[0073] An "oxo" group refers to a =0 group.
[0074] A "carboxylic acid" group refers to a C-carboxyl group in which R is hydrogen.
[0075] A "halo" group or "halogen" refers to fluorine, chlorine, bromine or iodine.
[0076] A "trihalomethyl" group refers to a -CX3 group wherein X is a halo group as defined herein, e.g., a CF3 group.
[0077] A "sulfinyl" group refers to an -S(=0)-R group, wherein R is as defined herein. [0078] A "sulfonyl" group refers to an -S(=0)2-R group, wherein R is as defined herein.
[0079] An "S-sulfonamido" group refers to a -S(=0)2- R2 group, with each of R as is defined herein.
[0080] An "N-sulfonamido" group refers to an RS(=0)2- R group, wherein each of R is as defined herein.
[0081] An "O-carbamyl" group refers to an -OC(=0)-NR2 group, wherein each of R is as defined herein.
[0082] An "N-carbamyl" group refers to an ROC(=0)- R- group, wherein each of R is as defined herein.
[0083] An "O-thiocarbamyl" group refers to an -OC(=S)-NR2 group, wherein each of R is as defined herein.
[0084] An "N-thiocarbamyl" group refers to an ROC(=S) R- group, wherein each of R is as defined herein.
[0085] An "amino" group refers to an - R2 group wherein each of R is as defined herein.
[0086] A "C-amido" group refers to a -C(=0)- R2 group, wherein each of R is as defined herein.
[0087] An "N-amido" group refers to an RC(=0)-NR- group, wherein each of R is as defined herein.
[0088] A "urea" group refers to an -NRC(=0)-NR2 group, wherein each of R is as defined herein.
[0089] A "guanidino" group refers to an -RNC(=N)-NR2 group, wherein each of R is as defined herein.
[0090] A "guanyl" group refers to an R2NC(=N)- group, wherein each of R is as defined herein.
[0091] The term "phosphonyl" or "phosphonate" describes a -P(=0)(OR)2 group, with R as defined herein.
[0092] The term "phosphate" describes an -0-P(=0)(OR)2 group, with each of R as defined herein.
[0093] A "phosphoric acid" is a phosphate group wherein each of R is hydrogen.
[0094] The term "phosphinyl" describes a -PR2 group, with each of R as defined herein.
[0095] The term "thiourea" describes a -NR-C(=S)-NR- group, with each of R as defined herein. [0096] The term "saccharide" refers to one or more sugar units, either an open-chain sugar unit or a cyclic sugar unit (e.g., pyranose- or furanose-based units), and encompasses any monosaccharide, disaccharide and oligosaccharide, unless otherwise indicated.
[0097] The term "stereoisomer" includes geometric isomers, such as E or Z isomers, enantiomers, diastereomers, and the like.
[0098] The term "stereoisomeric mixture" includes any mixture in any ratio of stereoisomers defined herein. In some embodiments, a stereoisomeric mixture includes a racemic mixture. In some embodiments, a stereoisomeric mixture includes an enantiomerically enriched mixture. In some embodiments, a stereoisomeric mixture includes a mixture of diastereomers in any ratio.
[0099] The term "enantiomeric excess" or "ee" refers to a measure for how much of one enantiomer is present compared to the other. For a mixture of R and S enantiomers, the percent enantiomeric excess is defined as | R - S | * 100, where R and S are the respective mole or weight fractions of enantiomers in a mixture such that R + S = 1. With knowledge of the optical rotation of a chiral substance, the percent enantiomeric excess is defined as ([ ]ObS/[a]max)* 100, where [ ]0bS is the optical rotation of the mixture of enantiomers and [a]max is the optical rotation of the pure enantiomer.
[0100] The term "salt" includes both internal salt or external salt. In some embodiments, the salt is an internal salt, i.e., a zwitterion structure. In some embodiments, the salt is an external salt. In some embodiments, the external salt is a pharmaceutically acceptable salt having a suitable counter ion. Suitable counterions for pharmaceutical use are known in the art.
[0101] Throughout this application, various embodiments of this invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range, such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5 and 6. This applies regardless of the breadth of the range.
[0102] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Oxidized Lipids
[0103] The present invention is directed, in part, to oxidized lipid compounds. In some embodiments, an oxidized lipid on the invention is a compound having a structure according to Formula 1 :
Formula 1
[0104] or a pharmaceutically acceptable salt, a hydrate or a solvate thereof,
[0105] wherein:
[0106] n is an integer from 1 to 6, wherein when n is 1, Cn, Bn, Rn, and Y are absent, and
Ci is attached to R'n; [0107] each of Bi, B2, ...Bn-1 and Bn is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, wherein each of said nitrogen, phosphorus and silicon is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo;
[0108] each of Ai, A2, ...An-1 and An is independently selected from the group consisting of CR"R"', C=0 and C=S,
[0109] Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4, 5 -biphosphonate, phosphoinositol-4, 5 -bi sphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, phosphoglycerol and a moiety having the general formula:
[0110] wherein:
[0111] each of B' and B" is independently selected from the group consisting of sulfur and oxygen; and
[0112] each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate; and
[0113] each of Xi, X2, ...Xn-1 is independently a saturated or unsaturated hydrocarbon having the general Formula 2: Ra Rb Rm-1 Rm
Ca Cb C m-1 Cm Z
R'a R'b R'm-1 R'm
Formula 2
[0114] wherein, m is an integer from 1 to 26; and
[0115] Z is selected from the group consisting of:
[0116] wherein W is selected from the group consisting of oxygen and sulfur;
[0117] wherein at least one of Xi, X2, ...Xn-1 comprises a Z other than hydrogen,
[0118] and wherein:
[0119] each of Ri, R'i, R2, ... Rn-1, Rn, Rn, each of R" and R" and each of Ra, Ra, Rb,
Rb, ...Rm-1, Rm-1, Rm and Rm is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aiyloxy, thiohydroxy, thioalkoxy, thioaiyloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O- carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of Ri, R'i, R2, ...Rn-1, Rn and Rn and/or at least two of Ra, Ra, Rb, R'b, ...Rm-1, Rm-1, Rm and R'm form at least one four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring,
[0120] or a pharmaceutically acceptable salt, a hydrate or a solvate thereof.
[0121] In other embodiments, an oxidized lipid on the invention is a compound having a structure according to Formula 3 :
Formula 3
[0122] or a pharmaceutically acceptable salt, hydrate or solvate thereof.
[0123] In Formula 3, n is an integer selected from 1 to 4.
[0124] In Formula 3, Bi, each B2, and B3 are independently selected from the group consisting of oxygen, sulfur, and R4, wherein R4 is selected from hydrogen, alkyl, cycloalkyl, aryl, and acyl.
[0125] In Formula 3, A1 and each A2 are independently selected from the group consisting of CReRee, CRe=CRee, C=0 and C=S, wherein Re and Ree are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
[0126] In Formula 3, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol, and a moiety having the general formula:
[0127] wherein:
[0128] each of B' and B" is independently selected from the group consisting of sulfur and oxygen; and
[0129] D' and D" are independently selected from the group consisting of hydrogen, alkyl, aminoalkyl, cycloalkyl, phosphonate and thiophosphonate.
[0130] In Formula 3, Xi and each X2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of X1 and X2 is substituted with an oxidized moiety Z selected from the group consisting of:
[0131] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
[0132] In one embodiment in Formula 3, Xi and each X2 independently have the general
Formula 4:
Formula 4
[0133] In Formula 4, m is an integer selected from 1 to 26.
[0134] In Formula 4, Z is selected from the group consisting
[0135] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl,
[0136] wherein at least one of X1 and X2 comprises a Z other than hydrogen. [0137] In Formula 3 and Formula 4, Ri, Ria, each R2, R3, R3a, R¾ Ra¾ each R , each R b,
Rc and RcC are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, tnhalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C- carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, wherein at least two of Ri, Ria, R2, R3 and R3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring, and wherein at least two of Ra, Raa, Rb, ¾b, Rc, and R;C are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring.
[0138] In one embodiment in Formula 3, n is 1 or 2. In another embodiment in Formula
3, n is 1.
[0139] In one embodiment in Formula 3, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
[0140] In another embodiment in Formula 3, Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine.
[0141] In another embodiment in Formula 3, Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
[0142] In one embodiment in Formula 3, Y is phosphoryl choline.
ORd
W=C
[0143] In one embodiment in Formula 3, Z is ' . In another embodiment in
Formula 3, Z is a carboxylic acid group.
[0144] In a further embodiment in Formula 3, n is 1 and Y is phosphoryl choline.
[0145] In a further embodiment in Formula 3, each of Bi, B2, and B3 is oxygen. [0146] In a further embodiment in Formula 3, n is 1, Y is phosphoryl choline, and each of
Bi, B2, and B3 is oxygen.
[0147] In one embodiment, the oxidized phospholipid useful in any of the methods of the present disclosure has a structure according to Formula 3a:
Formula 3a
[0148] or a pharmaceutically acceptable salt, hydrate or solvate thereof.
[0149] In Formula 3a, Bi, B2, and B3 are independently selected from oxygen and sulfur.
[0150] In Formula 3a, A1 and A2 are independently selected from the group consisting of
CH2, CH=CH, C=0 and C=S.
[0151] In Formula 3a, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol, and a moiety having the general formula:
[0152] wherein:
[0153] each of B' and B" is independently selected from the group consisting of sulfur and oxygen; and
[0154] each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate.
[0155] In Formula 3a, Ri, Ria, R2, R3, and R3a, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S- thiocarboxy and amino, wherein at least two of Ri, Ria, R2, R3 and R3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring, and wherein at least two of Ra, Ra¾ Rb, Rbb, Rc, and R;C are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring;
[0156] In Formula 3a, Xi and X2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of Xi and X2 is substituted with an oxidized moiety Z having a formula selected from:
[0157] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
[0158] In one embodiment in Formula 3a, Xi and X2 independently have a structure according to Formula 4a:
Formula 4a
[0159] In Formula 4a, m is an integer selected from 1 to 26.
[0160] In Formula 4a, Ra, Raa, each R , each R b, Rc, and RcC are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C- thiocarboxy, S-thiocarboxy and amino, wherein at least two of Ra, Raa, Rb, Rbb, Rc, and Rcc are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring.
[0161] In Formula 4a, Z is selected from the group consisting of:
[0162] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaiyl, wherein at least one of Xi and X2 comprises a Z other than hydrogen.
[0163] In one embodiment in Formula 3a, Z is In another embodiment in
Formula 3a, Z is a carboxylic acid group.
[0164] In one embodiment in Formula 3a, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)] , phosphoinositol-4-phosphate, phosphoinositol-4, 5 -bi sphosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
[0165] In one embodiment in Formula 3a, Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine.
[0166] In another embodiment in Formula 3a, Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
[0167] In one embodiment in Formula 3a, Y is phosphoryl choline.
[0168] In a further embodiment in Formula 3a, each of Bi, B2, and B3 is oxygen.
[0169] In a further embodiment in Formula 3a, Y is phosphoryl choline, and each of Bi,
B2, and B3 is oxygen.
[0170] In one embodiment in Formula 3a, the oxidized phospholipid has a structure according to Formula 4b:
H H H H C C C H
Bj B2 B3
A, A2 Y
X[ x2
Formula 4b
[0171] wherein Bi, B2, B3, Ai, A2, Xi, X2, and Y are defined as for Formula 3a.
[0172] In one embodiment, each of Bi, B2, B3 in Formula 4b is oxygen and the oxidized phospholipid has a structure according to the Formula 4c:
Formula 4c
[0173] In Formula 4c, A1 is selected from the group consisting of CH2, CH=CH and
C=0. In one example, A1 in Formula 4c is CH2.
[0174] In Formula 4c, A2 is absent or CH2.
[0175] In Formula 4c, X1 is an alkyl having from 1 to 30 carbon atoms.
[0176] In Formula 4c, X2 is
[0177] wherein
[0178] E is absent or is an alkyl chain having from 1 to 24 carbon atoms;
[0179] F is selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halide, acetoxy and aryl; and
[0180] Z is selected from the group consisting of:
[0181] wherein Rd is selected from H, alkyl and aryl.
[0182] In Formula 4c, Y is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N- [methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5- bisposphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol and a moiety having the general formula:
[0183] wherein:
[0184] each of B' and B" is independently selected from the group consisting of sulfur and oxygen; and
[0185] each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate.
[0186] In one embodiment in Formula 4c, X1 is alkyl having from 10 to 30 carbon atoms, or from 8 to 30 carbon atoms.
[0187] In one embodiment in Formula 4c, E is alkyl having from 1 to 10 carbon atoms, or from 1 to 4 carbon atoms.
[0188] In one embodiment in Formula 4c, Y is phosphoryl choline.
[0189] Each carbon atom in Formula 1, 2, 3, 3a, 4b and 4c is a chiral or non-chiral carbon atom, wherein each chiral carbon atom can have S-configuration or R-configuration.
[0190] In one embodiment, the oxidized lipid is l-hexadecyl-2-(4'-carboxy)butyl- glycero-3 -phosphocholine or 1 -hexadecyl-2-(4'-carboxybutyl)-glycero-3 -phosphocholine. As used herein, l-hexadecyl-2-(4'-carboxy)butyl-glycero-3 -phosphocholine and 1- hexadecyl-2-(4'-carboxybutyl)-glycero-3 -phosphocholine are the same and both refer to the same compound, VB-201. VB-201 according to embodiments of this application may be a chiral enantiomer of l-hexadecyl-2-(4'-carboxybutyl)-glycero-3 -phosphocholine, i.e., either the (R)- enantiomer (( ?)-l-hexadecyl-2-(4'-carboxybutyl)-5«-glycero-3- phosphocholine) or the (S)- enantiomer ( ¾)-l-hexadecyl-2-(4'-carboxybutyl)-sn-glycero- 3 -phosphocholine), or a mixture thereof (e.g., a racemate). In one embodiment, the oxidized phospholipid is ( ?)-l-hexadecyl-2-(4'-carboxy)butyl-5«-glycero-3- phosphocholine. In some embodiments, the ( ?)-l-hexadecyl-2-(4'-carboxy)butyl-5«- glycero-3 -phosphocholine has an enantiomeric purity of about 80% ee or more, e.g., about 85% ee, about 90% ee, about 91% ee, about 92% ee, about 93% ee, about 94% ee, about 95% ee, about 96% ee, about 97% ee, about 98% ee, about 99% ee, about 99.5% ee or more. In other embodiments, the ( ?)-l-hexadecyl-2-(4'-carboxy)butyl-5«-glycero-3- phosphocholine has an enantiomeric purity of from about 80% ee to about 100% ee, about 85%) ee to about 100% ee, about 90% ee to about 100% ee, about 95% ee to about 100%, about 80% ee to about 99.5% ee, about 85% ee to about 99.5% ee, about 90% ee to about 99.5%) ee, about 95% ee to about 99.5%, or any range thereof.
[0191] In other embodiments, the oxidized lipid has the following structure:
[0192] In other embodiments, the oxidized lipid has the following structure:
[0193] In some embodiments, an oxidized lipid compound of the invention treats or prevents fibrosis (e.g., liver fibrosis, kidney fibrosis, focal and segmental glomerulosclerosis, or any other fibrosis described herein) as well as, or better than, telmisartan. In other embodiments, an oxidized lipid compound of the invention reduces liver inflammation as well as, or better than, telmisartan. In other embodiments, an oxidized lipid compound of the invention reduces liver fibrosis as well as, or better than, telmisartan. In other embodiments, an oxidized lipid compound of the invention treats or prevents kidney fibrosis as well as, or better than, telmisartan. In other embodiments, an oxidized lipid compound of the invention treats or prevents focal and segmental glomerulosclerosis as well as, or better than, telmisartan.
[0194] Methods for synthesizing oxidized lipids of the invention have been described in, for example, International Publication Nos. WO 04/106486, WO 02/41827, and WO 2011/083469.
Pharmaceutical Compositions
[0195] Other embodiments of the invention relate to a pharmaceutical composition comprising an oxidized lipid of the invention. In some embodiments, the pharmaceutical composition comprises an oxidized lipid of the invention and a pharmaceutically acceptable vehicle. In other embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the oxidized lipid. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the oxidized lipid and a pharmaceutically acceptable vehicle. As used herein, a therapeutically effective amount of an oxidized lipid is an amount effective to treat or prevent a disease or disorder of the present invention.
[0196] In other embodiments, the pharmaceutical compositions of the present invention can be orally administered.
[0197] In other embodiments, the pharmaceutical composition comprises a compound having a structure according to Formula 1 :
Formula 1
[0198] or a pharmaceutically acceptable salt, a hydrate or a solvate thereof,
[0199] wherein:
[0200] n is an integer from 1 to 6, wherein when n is 1, Cn, Bn, Rn, and Y are absent, and
Ci is attached to R'n;
[0201] each of Bi, B2, ...Bn-1 and Bn is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, wherein each of said nitrogen, phosphorus and silicon is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo;
[0202] each of Ai, A2, ...An-1 and An is independently selected from the group consisting of CR"R", C=0 and C=S,
[0203] Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4, 5 -biphosphonate, phosphoinositol-4, 5 -bi sphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, phosphoglycerol and a moiety having the general formula:
[0204] wherein:
[0205] each of B' and B" is independently selected from the group consisting of sulfur and oxygen; and
[0206] each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate; and
[0207] each of Xi, X2, ...Xn-1 is independently a saturated or unsaturated hydrocarbon having the general Formula 2:
Ra Rb Rm-1 Rm
-Ca Cb- -C m-1 Cm-
R'a R'b R'm-1 R'm
Formula 2
[0208] wherein, m is an integer from 1 to 26; and
[0209] Z is selected from the group consisting of:
R"
OR" R'
W=
/ \ w=C CH
H, W=C^ ° , \ WR'" and -OR".
[0210] wherein W is selected from the group consisting of oxygen and sulfur;
[0211] wherein at least one of Xi, X2, ...Xn-1 comprises a Z other than hydrogen,
[0212] and wherein:
[0213] each of Rb R'b R2, ... Rn-1, Rn, Rn, each of R" and R" and each of Ra, Ra, Rb,
Rb, ...Rm-1, Rm-1, Rm and Rm is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aiyloxy, thiohydroxy, thioalkoxy, thioaiyloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O- carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of Ri, R'i, R2, ...Rn-1, Rn and R'n and/or at least two of Ra, R'a, Rb, R'b, ...Rm-1, R'm-1, Rm and R'm form at least one four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring,
[0214] or a pharmaceutically acceptable salt, a hydrate or a solvate thereof.
[0215] In other embodiments, the pharmaceutical composition comprises a compound having a structure according to Formula 3 :
Formula 3
[0216] or a pharmaceutically acceptable salt, hydrate or solvate thereof.
[0217] In Formula 3, n is an integer selected from 1 to 4.
[0218] In Formula 3, Bi, each B2, and B3 are independently selected from the group consisting of oxygen, sulfur, and R4, wherein R4 is selected from hydrogen, alkyl, cycloalkyl, aryl, and acyl.
[0219] In Formula 3, Ai and each A2 are independently selected from the group consisting of CReRee, CRe=CRee, C=0 and C=S, wherein Re and Ree are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
[0220] In Formula 3, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol, and a moiety having the general formula:
[0221] wherein:
[0222] each of B and Ba is independently selected from the group consisting of sulfur and oxygen; and
[0223] D and Da are independently selected from the group consisting of hydrogen, alkyl, aminoalkyl, cycloalkyl, phosphonate and thiophosphonate.
[0224] In Formula 3, Xi and each X2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of Xi and X2 is substituted with an oxidized moiety Z selected from the group consisting of:
[0225] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
[0226] In one embodiment in Formula 3, Xi and each X2 independently have the general
Formula 4:
Formula 4 [0227] In Formula 4, m is an integer selected from 1 to 26.
[0228] In Formula 4, Z is selected from the group consisting of:
[0229] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaiyl,
[0230] wherein at least one of X1 and X2 comprises a Z other than hydrogen.
[0231] In Formula 3 and Formula 4, Ri, Ria, each R2, R3, R3a, Ra, Ra¾ each R , each R b,
Rc and RcC are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, tnhalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C- carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, wherein at least two of Ri, Ria, R2, R3 and R3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring, and wherein at least two of Ra, Raa, Rb, Rbb, Rc, and RcC are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring.
[0232] In one embodiment in Formula 3, n is 1 or 2. In another embodiment in Formula
3, n is 1.
[0233] In one embodiment in Formula 3, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol. [0234] In another embodiment in Formula 3, Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine.
[0235] In another embodiment in Formula 3, Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
[0236] In one embodiment in Formula 3, Y is phosphoryl choline.
ORd
W=C
[0237] In one embodiment in Formula 3, Z is ' . In another embodiment in
Formula 3, Z is a carboxylic acid group.
[0238] In a further embodiment in Formula 3, n is 1 and Y is phosphoryl choline.
[0239] In a further embodiment in Formula 3, each of Bi, B2, and B3 is oxygen.
[0240] In a further embodiment in Formula 3, n is 1, Y is phosphoryl choline, and each of
Bi, B2, and B3 is oxygen.
[0241] In one embodiment, the pharmaceutical composition comprises a compound having a structure according to Formula 3a:
Formula 3a
[0242] or a pharmaceutically acceptable salt, hydrate or solvate thereof.
[0243] In Formula 3a, Bi, B2, and B3 are independently selected from oxygen and sulfur.
[0244] In Formula 3a, A1 and A2 are independently selected from the group consisting of
CH2, CH=CH, C=0 and C=S.
[0245] In Formula 3a, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- di ethyl enetri amine-pentaacetate, dinitropheny 1 -pho sphoethanol amine, and phosphoglycerol.
In Formula 3a, Ri, Ria, R2, R3, and R3a, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S- thiocarboxy and amino, wherein at least two of Ri, Ria, R2, R3 and R3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring, and wherein at least two of Ra, Raa, R , Rbb, Rc, and R;C are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring;
In Formula 3a, Xi and X2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of Xi and X2 is substituted with an oxidized moiety Z having a formula selected from:
[0248] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
[0249] In one embodiment in Formula 3a, Xi and X2 independently have a structure according to Formula 4a:
Formula 4a
[0250] In Formula 4a, m is an integer selected from 1 to 26.
[0251] In Formula 4a, Ra, Ra¾ each R , each R b, Rc, and RcC are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C- thiocarboxy, S-thiocarboxy and amino, wherein at least two of Ra, Raa, Rb, Rbb, Rc, and Rcc are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring.
[0252] In Formula 4a, Z is selected from the group consisting of:
[0253] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaiyl, wherein at least one of Xi and X2 comprises a Z other than hydrogen.
[0254] In one embodiment in Formula 3a, Z is In another embodiment in
Formula 3a, Z is a carboxylic acid group.
[0255] In one embodiment in Formula 3a, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)] , phosphoinositol-4-phosphate, phosphoinositol-4, 5 -bi sphosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
[0256] In one embodiment in Formula 3a, Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine.
[0257] In another embodiment in Formula 3a, Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
[0258] In one embodiment in Formula 3a, Y is phosphoryl choline.
[0259] In a further embodiment in Formula 3a, each of Bi, B2, and B3 is oxygen.
[0260] In a further embodiment in Formula 3a, Y is phosphoryl choline, and each of Bi,
B2, and B3 is oxygen.
[0261] In one embodiment in Formula 3a, the oxidized phospholipid has a structure according to Formula 4b:
H H H H C C C H
Bj B2 B3
A, A2 Y
X] x2
Formula 4b
[0262] wherein Bi, B2, B3, Ai, A2, Xi, X2, and Y are defined as for Formula 3a.
[0263] In one embodiment, each of Bi, B2, B3 in Formula 4b is oxygen and the oxidized phospholipid has a structure according to the Formula 4c:
Formula 4c
[0264] In Formula 4c, Ai is selected from the group consisting of CH2, CH=CH and
C=0. In one example, Ai in Formula 4c is CH2.
[0265] In Formula 4c, A2 is absent or CH2.
[0266] In Formula 4c, Xi is an alkyl having from 1 to 30 carbon atoms.
[0267] In Formula 4c, X2 is
[0268] wherein
[0269] E is absent or is an alkyl chain having from 1 to 24 carbon atoms;
[0270] F is selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halide, acetoxy and aryl; and
[0271] Z is selected from the group consisting of:
[0272] wherein R is selected from H, alkyl and aryl.
[0273] In Formula 4c, Y is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N- [methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5- bisposphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol.
[0274] In one embodiment in Formula 4c, X1 is alkyl having from 10 to 30 carbon atoms, or from 8 to 30 carbon atoms.
[0275] In one embodiment in Formula 4c, E is alkyl having from 1 to 10 carbon atoms, or from 1 to 4 carbon atoms.
[0276] In one embodiment in Formula 4c, Y is phosphoryl choline.
[0277] Each carbon atom in Formula 1, 2, 3, 3a, 4b and 4c is a chiral or non-chiral carbon atom, wherein each chiral carbon atom can have S-configuration or R-configuration.
[0278] In another embodiment, the pharmaceutical compositions of the invention comprise l-hexadecyl-2-(4'-carboxy)butyl-glycero-3-phosphocholine or l-hexadecyl-2- (4'-carboxybutyl)-glycero-3-phosphocholine (VB-201). In another embodiment, the pharmaceutical compositions of the invention comprise ( ?)-l-hexadecyl-2-(4l- carboxy)butyl-s«-glycero-3-phosphocholine. In some embodiments, the (K -l-hexadecyl- 2-(4'-carboxy)butyl-s«-glycero-3-phosphocholine has an enantiomeric purity of about 80% ee or more, e.g., about 85%> ee, about 90% ee, about 91% ee, about 92% ee, about 93% ee, about 94% ee, about 95% ee, about 96% ee, about 97% ee, about 98% ee, about 99%) ee, about 99.5% ee or more. In other embodiments, the ( ?)-l-hexadecyl-2-(4l- carboxy)butyl-s«-glycero-3-phosphocholine has an enantiomeric purity of from about 80% ee to about 100% ee, about 85% ee to about 100% ee, about 90% ee to about 100% ee, about 95% ee to about 100%, about 80% ee to about 99.5% ee, about 85% ee to about 99.5% ee, about 90% ee to about 99.5% ee, about 95% ee to about 99.5%, or any range thereof.
[0279] In other embodiments, the pharmaceutical compositions of the invention comprise a compound of the following structure:
In other embodiments, the pharmaceutical compositions of the invention compri a compound of the following structure:
In other embodiments, the pharmaceutical composition treats or prevents fibrosis
(e.g., liver fibrosis, kidney fibrosis, focal and segmental glomerulosclerosis, or any other fibrosis described herein) as well as, or better than, telmisartan. In other embodiments, the pharmaceutical composition reduces liver inflammation as well as, or better than, telmisartan. In other embodiments, the pharmaceutical composition reduces liver fibrosis as well as, or better than, telmisartan. In other embodiments, the pharmaceutical composition treats or prevents kidney fibrosis as well as, or better than, telmisartan. In other embodiments, the pharmaceutical composition treats or prevents focal and segmental glomerulosclerosis as well as, or better than, telmisartan. Methods of Treating or Preventing Fibrosis
[0282] Embodiments of the invention relate to a method for treating or preventing fibrosis or liver inflammation comprising administering an oxidized lipid of the invention. In other embodiments, the method comprises administering a therapeutically effective amount of an oxidized lipid of the invention to a subject in need thereof. In other embodiments, the method comprises administering a pharmaceutical composition of the invention.
[0283] In some embodiments of the methods of the invention, the fibrosis is pulmonary fibrosis, liver fibrosis, skin fibrosis, or kidney fibrosis. In some embodiments of the methods of the invention, the fibrosis is heart fibrosis, bone marrow fibrosis, intestine fibrosis, joint fibrosis (knee, shoulder, or other joints), hand fibrosis, finger fibrosis, skeletal muscle fibrosis, neurofibrosis, and penis fibrosis. In other embodiments, the fibrosis is idiopathic pulmonary fibrosis (IPF), cystic fibrosis, progressive massive fibrosis, cirrhosis, steatohepatitis (fatty liver disease), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), endomyocardial fibrosis, myocardial infarction, atrial fibrosis, medastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, nephrogenic systemic fibrosis, keloid, Crohn's disease, scleroderma/systemic sclerosis, arthrofibrosis, Peyronie's disease, Dupuytren's contracture, adhesive capsulitis, or focal and segmental glomerulosclerosis. In some embodiments the fibrosis is associated with liver inflammation. In some embodiments, the fibrosis is liver fibrosis. In some embodiments, the fibrosis is kidney fibrosis. In some embodiments, the subject in need of treatment or prevention of kidney fibrosis has a chronic kidney disease. In some embodiments, the fibrosis is focal and segmental glomerulosclerosis. In some embodiments, the subject in need of treatment or prevention of focal and segmental glomerulosclerosis has a chronic kidney disease.
[0284] In some embodiments, the fibrosis is a fibrosis that does not include idiopathic pulmonary fibrosis. In other embodiments, the fibrosis is a fibrosis that does not include cystic fibrosis. In other embodiments, the fibrosis is a fibrosis that does not include progressive massive fibrosis. In some embodiments, the fibrosis is a fibrosis that does not include cirrhosis. In some embodiments, the fibrosis is a fibrosis that does not include steatohepatitis (fatty liver disease). In some embodiments, the fibrosis is a fibrosis that does not include nonalcoholic fatty liver disease (NAFLD). In some embodiments, the fibrosis is a fibrosis that does not include nonalcoholic steatohepatitis (NASH). In some embodiments, the fibrosis is a fibrosis that does not include endomyocardial fibrosis. In some embodiments, the fibrosis is a fibrosis that does not include myocardial infarction. In some embodiments, the fibrosis is a fibrosis that does not include atrial fibrosis. In some embodiments, the fibrosis is a fibrosis that does not include medastinal fibrosis. In some embodiments, the fibrosis is a fibrosis that does not include myelofibrosis. In some embodiments, the fibrosis is a fibrosis that does not include retroperitoneal fibrosis. In some embodiments, the fibrosis is a fibrosis that does not include nephrogenic systemic fibrosis. In some embodiments, the fibrosis is a fibrosis that does not include keloid. In some embodiments, the fibrosis is a fibrosis that does not include Crohn's disease. In some embodiments, the fibrosis is a fibrosis that does not include scleroderma/systemic sclerosis. In some embodiments, the fibrosis is a fibrosis that does not include arthrofibrosis. In some embodiments, the fibrosis is a fibrosis that does not include Peyronie's disease. In some embodiments, the fibrosis is a fibrosis that does not include Dupuytren's contracture. In some embodiments, the fibrosis is a fibrosis that does not include adhesive capsulitis. In some embodiments, the fibrosis is a fibrosis that does not include focal and segmental glomerulosclerosis. In some embodiments, the fibrosis is a fibrosis that does not include fibrous lesions or plaques in the arteries.
[0285] In some embodiments, the oxidized lipid treats or prevents liver inflammation, but does not alter liver fibrosis. In other embodiments, the oxidized lipid treats or prevents liver fibrosis, but does not alter liver inflammation.
[0286] In some embodiments of the methods of the invention, activity of TLR2, TLR4 and/or CD14 is inhibited in a treated cell. In some embodiments, activity of TLR2 and TLR4 is inhibited; activity of TLR4 and CD14 is inhibited; activity of TLR2 and CD14 is inhibited; or activity of TLR2, TLR4 and CD14 is inhibited.
[0287] In some embodiments of the methods of the invention, steatosis in a subject treated with an oxidized lipid of the invention is not reduced, compared to that in untreated or placebo-treated subjects. In other embodiments, liver lobular formation in a subject treated with an oxidized lipid of the invention is decreased, compared to that in untreated or placebo-treated subjects. In other embodiments, liver lobular formulation in a subject treated with an oxidized lipid of the invention is not decreased, compared to that in untreated or placebo-treated subjects. In other embodiments, steatosis in a subject treated with an oxidized lipid of the invention is not reduced and liver lobular formation in a subject treated with an oxidized lipid of the invention is decreased, compared to those in untreated or placebo-treated subjects, respectively. In other embodiments, steatosis in a subject treated with an oxidized lipid of the invention is not reduced and liver lobular formation in a subject treated with an oxidized lipid of the invention is not decreased, compared to those in untreated or placebo-treated subjects, respectively. In other embodiments, foam cell-like macrophages are decreased in a subject treated with an oxidized lipid of the invention, compared to that in untreated or placebo-treated subjects. In some embodiments, liver lobular formation and foam cell-like macrophages in a subject treated with an oxidized lipid of the invention are decreased, compared to those in untreated or placebo-treated subjects, respectively. In some embodiments, liver lobular inflammation in a subject treated with an oxidized lipid of the invention is decreased, compared to that in untreated or placebo-treated subjects. In some embodiments, liver lobular inflammation and foam cell-like macrophages in a subject treated with an oxidized lipid of the invention are decreased, compared to those in untreated or placebo- treated subjects, respectively. In some embodiments, liver lobular formation, liver lobular inflammation and foam cell-like macrophages in a subject treated with an oxidized lipid of the invention are decreased, compared to those in untreated or placebo- treated subjects, respectively. In some embodiments, liver lobular formation in a subject treated with an oxidized lipid of the invention is decreased by about 5% to about 50% (e.g., about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, or any ranges between the specified values) compared to that in untreated or placebo-treated subjects. In some embodiments, the formation of foam cell-like macrophages in a subject treated with an oxidized lipid of the invention is decreased by about 5% to about 50% (e.g., about 5%), about 10%), about 20%, about 30%, about 40%, about 50%, or any ranges between the specified values) compared to that in untreated or placebo-treated subjects. In some embodiments, liver lobular inflammation in a subject treated with an oxidized lipid of the invention is decreased by about 5% to about 50% (e.g., about 5%, about 10%, about 20%, about 30%), about 40%, about 50%, or any ranges between the specified values) compared to that in untreated or placebo-treated subjects.
In some embodiments, the oxidized lipid is a compound having a structure according to Formula 1 :
Formula 1
[0289] or a pharmaceutically acceptable salt, a hydrate or a solvate thereof,
[0290] wherein:
[0291] n is an integer from 1 to 6, wherein when n is 1, Cn, Bn, Rn, and Y are absent, and
Ci is attached to R'n;
[0292] each of Bi, B2, ...Bn-1 and Bn is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, wherein each of said nitrogen, phosphorus and silicon is optionally substituted by one or more substituents selected from the group consisting of alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo;
[0293] each of Ai, A2, ...An-1 and An is independently selected from the group consisting of CR"R", C=0 and C=S,
[0294] Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4, 5 -biphosphonate, phosphoinositol-4, 5 -bi sphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, phosphoglycerol and a moiety having the general formula: B'\
D'
[0295] wherein:
[0296] each of B' and B" is independently selected from the group consisting of sulfur and oxygen; and
[0297] each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate; and
[0298] each of Xi, X2, ...Xn-1 is independently a saturated or unsaturated hydrocarbon having the general Formula 2:
Ra Rb Rm-1 Rm
Ca Cb C m-1 Cm Z
R'a R'b R'm-l R'm
Formula 2 wherein, m is an integer from 1 to 26; and
Z is selected from the group consisting of:
R"
OR" R"
w= /
w= \ w=c — CH
H, \ o W '" and -OR
[0300] wherein W is selected from the group consisting of oxygen and sulfur;
[0301] wherein at least one of Xi, X2, ...Xn-1 comprises a Z other than hydrogen,
[0302] and wherein:
[0303] each of Rb R'b R2, ... Rn-1, Rn, Rn, each of R" and R" and each of Ra, Ra, Rb,
Rb, ...Rm-1, R'm-l, Rm and Rm is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aiyloxy, thiohydroxy, thioalkoxy, thioaiyloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O- carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of Ri, R'i, R2, ...Rn-1, Rn and R'n and/or at least two of Ra, R'a, Rb, R'b, ...Rm-1, R'm-1, Rm and R'm form at least one four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring,
[0304] or a pharmaceutically acceptable salt, a hydrate or a solvate thereof.
[0305] In other embodiments, the oxidized lipid is a compound having a structure according to Formula 3 :
Formula 3
[0306] or a pharmaceutically acceptable salt, hydrate or solvate thereof.
[0307] In Formula 3, n is an integer selected from 1 to 4.
[0308] In Formula 3, Bi, each B2, and B3 are independently selected from the group consisting of oxygen, sulfur, and R4, wherein R4 is selected from hydrogen, alkyl, cycloalkyl, aryl, and acyl.
[0309] In Formula 3, Ai and each A2 are independently selected from the group consisting of CReRee, CRe=CRee, C=0 and C=S, wherein Re and Ree are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
[0310] In Formula 3, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol, and a moiety having the general formula:
[0311] wherein:
[0312] each of B and Bais independently selected from the group consisting of sulfur and oxygen; and
[0313] D and Da are independently selected from the group consisting of hydrogen, alkyl, aminoalkyl, cycloalkyl, phosphonate and thiophosphonate.
[0314] In Formula 3, Xi and each X2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of Xi and X2 is substituted with an oxidized moiety Z selected from the group consisting of:
[0315] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
[0316] In one embodiment in Formula 3, Xi and each X2 independently have the general
Formula 4:
Formula 4
[0317] In Formula 4, m is an integer selected from 1 to 26. [0318] In Formula 4, Z is selected from the group consisting of:
[0319] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaiyl,
[0320] wherein at least one of X1 and X2 comprises a Z other than hydrogen.
[0321] In Formula 3 and Formula 4, Ri, Ria, each R2, R3, R3a, Ra, Ra¾ each R , each R b,
Rc and RcC are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, tnhalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C- carbamate, N-carbamate, C-thiocarboxy, S-thiocarboxy and amino, wherein at least two of Ri, Ria, R2, R3 and R3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring, and wherein at least two of Ra, Raa, Rb, Rbb, Rc, and R;C are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring.
[0322] In one embodiment in Formula 3, n is 1 or 2. In another embodiment in Formula
3, n is 1.
[0323] In one embodiment in Formula 3, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
[0324] In another embodiment in Formula 3, Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine. [0325] In another embodiment in Formula 3, Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
[0326] In one embodiment in Formula 3, Y is phosphoryl choline.
[0327] In one embodiment in Formula 3, Z is . In another embodiment in
Formula 3, Z is a carboxylic acid group.
[0328] In a further embodiment in Formula 3, n is 1 and Y is phosphoryl choline.
[0329] In a further embodiment in Formula 3, each of Bi, B2, and B3 is oxygen.
[0330] In a further embodiment in Formula 3, n is 1, Y is phosphoryl choline, and each of
Bi, B2, and B3 is oxygen.
[0331] In one embodiment, the oxidized lipid has a structure according to Formula 3a:
Formula 3 a
[0332] or a pharmaceutically acceptable salt, hydrate or solvate thereof.
[0333] In Formula 3a, Bi, B2, and B3 are independently selected from oxygen and sulfur.
[0334] In Formula 3a, A1 and A2 are independently selected from the group consisting of
CH2, CH=CH, C=0 and C=S.
[0335] In Formula 3a, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphoryl ethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4- phosphate, phosphoinositol-4,5-bisphosphate, pyrophosphate, phosphoethanolamine- di ethyl enetri amine-pentaacetate, dinitropheny 1 -pho sphoethanol amine, and phosphoglycerol.
[0336] In Formula 3a, Ri, Ria, R2, R3, and R3a, are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C-thiocarboxy, S- thiocarboxy and amino, wherein at least two of Ri, Ria, R2, R3 and R3a are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring, and wherein at least two of Ra, Ra¾ Rb, Rbb, Rc, and R;C are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring;
[0337] In Formula 3a, X1 and X2 are independently a saturated or unsaturated, linear or branched hydrocarbon, wherein at least one of X1 and X2 is substituted with an oxidized moiety Z having a formula selected from:
[0338] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl.
[0339] In one embodiment in Formula 3a, X1 and X2 independently have a structure according to Formula 4a:
Formula 4a [0340] In Formula 4a, m is an integer selected from 1 to 26.
[0341] In Formula 4a, Ra, Raa, each Rb, each Rbb, R^, and RcC are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaiyl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N-carbamate, C- thiocarboxy, S-thiocarboxy and amino, wherein at least two of Ra, Raa, Rb, ¾b, Rc, and Rcc are optionally joined to form a four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring.
[0342] In Formula 4a, Z is selected from the group consisting of:
[0343] wherein W is oxygen or sulfur; and Rd and Rdd are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaiyl, wherein at least one of Xi and X2 comprises a Z other than hydrogen.
ORd
w=c
[0344] In one embodiment in Formula 3a, Z is x . In another embodiment in
Formula 3a, Z is a carboxylic acid group.
[0345] In one embodiment in Formula 3a, Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)] , phosphoinositol-4-phosphate, phosphoinositol-4, 5 -bi sphosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, and phosphoglycerol.
[0346] In one embodiment in Formula 3a, Y is selected from the group consisting of hydrogen, phosphoryl choline, and phosphoryl ethanolamine. [0347] In another embodiment in Formula 3a, Y is selected from the group consisting of phosphoryl choline, and phosphoryl ethanolamine.
[0348] In one embodiment in Formula 3a, Y is phosphoryl choline.
[0349] In a further embodiment in Formula 3a, each of Bi, B2, and B3 is oxygen.
[0350] In a further embodiment in Formula 3a, Y is phosphoryl choline, and each of Bi,
B2, and B3 is oxygen.
[0351] In one embodiment in Formula 3a, the oxidized phospholipid has a structure according to Formula 4b:
H H H
H C C C H
B, B B
A, A2 Y
Xl X2
Formula 4b
[0352] wherein Bi, B2, B3, Ai, A2, Xi, X2, and Y are defined as for Formula 3a.
[0353] In one embodiment, each of Bi, B2, B3 in Formula 4b is oxygen and the oxidized phospholipid has a structure according to the Formula 4c:
Formula 4c [0354] In Formula 4c, A1 is selected from the group consisting of CH2, CH=CH and
C=0. In one example, A1 in Formula 4c is CH2.
[0355] In Formula 4c, A2 is absent or CH2.
[0356] In Formula 4c, X1 is an alkyl having from 1 to 30 carbon atoms.
[0357] In Formula 4c, X2 is
[0358] wherein
[0359] E is absent or is an alkyl chain having from 1 to 24 carbon atoms;
[0360] F is selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halide, acetoxy and aryl; and
[0361] Z is selected from the group consisting of:
[0362] wherein Rd is selected from H, alkyl and aryl.
[0363] In Formula 4c, Y is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N- [methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5- bisposphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, and phosphoglycerol.
[0364] In one embodiment in Formula 4c, X1 is alkyl having from 10 to 30 carbon atoms, or from 8 to 30 carbon atoms.
[0365] In one embodiment in Formula 4c, E is alkyl having from 1 to 10 carbon atoms, or from 1 to 4 carbon atoms.
[0366] In one embodiment in Formula 4c, Y is phosphoryl choline. [0367] Each carbon atom in Formula 1, 2, 3, 3a, 4b, and 4c is a chiral or non-chiral carbon atom, wherein each chiral carbon atom can have S-configuration or R- configuration.
[0368] In another embodiment, the oxidized lipid is l-hexadecyl-2-(4'-carboxy)butyl- glycero-3 -phosphocholine or 1 -hexadecyl-2-(4'-carboxybutyl)-glycero-3 -phosphocholine (VB-201). In another embodiment, the oxidized lipid is 7^)-l-hexadecyl-2-(4'- carboxy)butyl-s«-glycero-3 -phosphocholine. In some embodiments, the K -l-hexadecyl- 2-(4'-carboxy)butyl-s«-glycero-3 -phosphocholine has an enantiomeric purity of about 80% ee or more, e.g., about 85%> ee, about 90%> ee, about 91%> ee, about 92%> ee, about 93% ee, about 94% ee, about 95% ee, about 96% ee, about 97% ee, about 98% ee, about 99%) ee, about 99.5%> ee or more. In other embodiments, the ( ?)-l-hexadecyl-2-(4l- carboxy)butyl-s«-glycero-3 -phosphocholine has an enantiomeric purity of from about 80% ee to about 100% ee, about 85% ee to about 100% ee, about 90% ee to about 100% ee, about 95%> ee to about 100%>, about 80%> ee to about 99.5%> ee, about 85%> ee to about 99.5% ee, about 90% ee to about 99.5% ee, about 95% ee to about 99.5%, or any range thereof.
[0369] In other embodiments, the oxidized lipid has the following structure:
[0370] In other embodiments, the oxidized lipid has the following structure:
[0371] In other embodiments, the oxidized lipid compound treats or prevents fibrosis
(e.g., liver fibrosis, kidney fibrosis, focal and segmental glomerulosclerosis, or any other fibrosis described herein) as well as, or better than, telmisartan. In other embodiments, the oxidized lipid compound reduces liver inflammation as well as, or better than, telmisartan. In other embodiments, the oxidized lipid compound reduces liver fibrosis as well as, or better than, telmisartan. In other embodiments, the oxidized lipid compound treats or prevents kidney fibrosis as well as, or better than, telmisartan. In other embodiments, the oxidized lipid compound treats or prevents focal and segmental glomerulosclerosis as well as, or better than, telmisartan.
[0372] In some embodiments, the subject is a mammal or a human. In other embodiments, the human is a female. In other embodiments, the human is a male.
EXAMPLES
[0373] Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non-limiting fashion.
Example 1
VB-201 Inhibits LPS (TL 4)-Induced Signaling in Human monocytes (primary
CD 14+)
Methods and Materials
Isolation of monocytes
[0374] Venous blood samples were obtained from healthy male donors in compliance with the Institutional Review Board at the Sheba Medical Center, Ramat Gan, Israel. PBMCs were isolated on Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) using 50 ml Leucosep tubes (Greiner Bio-One, Frickenhausen, Germany). Cells were washed in PBS (Kibbutz Beit Haemek, Israel) and incubated at 4 °C for 15 minutes in a buffer containing PBS and 0.5% bovine serum albumin (BSA) with human CD 14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).
Activation of cells and Western blotting
[0375] Cells (106/ml) were pretreated for 20 min with VB-201 at the doses indicated in
Figure 1, or with solvent (Sol), followed by 15 min activation with 100 ng/ml lipopolysaccharide (LPS) or were untreated (Unt). Cells were washed and resuspended in lysis buffer containing 1 : 100 dithiothreitol (DTT), phosphatase and protease inhibitors (Thermo Scientific). Samples were loaded onto a precast Criterion TGX gel (Bio-Rad, Hemel Hempstead, UK) and transferred onto nitrocellulose membrane. Blots were blocked with 5% milk or BSA in Tris buffered saline and Tween 20 (TBST) for 1 h, followed by incubation with primary and secondary antibodies. Membranes were developed using an ECL kit (Thermo Scientific). The following antibodies were used for immunoblotting:
[0376] Primary antibodies: p-p38 (Cat. No. 4511; 1 : 1000) and p-IKK (Cat. No. 2697;
1 : 1000) were from Cell Signaling Technology (Danvers, MA, USA). p-ERKl/2 (Cat. No.
M8159; 1 : 10 000) was purchased from Sigma (Israel). aTubulin (Tub) or Heat Shock
Protein 90 (HSP90) served as a loading control.
[0377] Secondary antibodies: HRP donkey anti-rabbit (1 :5000) and HRP goat anti-mouse
(1 :3000) were from Jackson ImmunoRe search (West Grove, PA, USA). HRP donkey anti-goat (1 :5000) was from Santa Cruz Biotechnology. Results
[0378] To determine the effect of VB-201 on TLR4-mediated signaling pathways, isolated human primary monocytes (CD14+) were preincubated with VB-201 and then activated with LPS. Figures 1A-1D show that VB-201 inhibits formation of p-IKK, p- ERK and p-p38 and p-AKT induced by LPS in human monocytes in a dose dependent manner. Accordingly, VB-201 inhibits LPS (TLR4)-induced signaling.
Example 2
VB-201 Inhibits PGN (TLR2)-Induced Signaling in human monocytes (THP-1 cell line)
Methods and Materials
Activation of cells and Western blotting
[0379] The monocytic TFIP-1 cell line was purchased from the American Type Tissue
Culture Collection (ATCC Cat. No. TIB-202). Cells (106/ml) were pretreated for 20 min with VB-201 at the doses indicated in Figure 2, or with solvent, followed by activation with 20 μg/ml peptidoglycan (PGN) (InvivoGen, San Diego, CA) for 15 minutes, or were untreated ("Unt"). Cells were washed and resuspended in lysis buffer containing 1 : 100 dithiothreitol (DTT), phosphatase and protease inhibitors (Thermo Scientific). Samples were loaded onto a precast Criterion TGX gel (Bio-Rad, Hemel Hempstead, UK) and transferred onto nitrocellulose membrane. Blots were blocked with 5% milk or BSA in Tris buffered saline and Tween 20 (TBST) for 1 h, followed by incubation with primary and secondary antibodies. Membranes were developed using an ECL kit (Thermo Scientific). The following antibodies were used for immunoblotting:
[0380] Primary antibodies: p-p38 (Cat. No. 4511; 1 : 1000) and p-IKK (Cat. No. 2697;
1 : 1000) were from Cell Signaling Technology (Danvers, MA, USA). p-ERKl/2 (Cat. No. M8159; 1 : 10000) was purchased from Sigma (Israel). aTubulin served as a loading control.
[0381] Secondary antibodies: HRP donkey anti-rabbit (1 :5000) and HRP goat anti-mouse
(1 :3000) were from ackson ImmunoRe search (West Grove, PA, USA). HRP donkey anti-goat (1 :5000) was from Santa Cruz Biotechnology. Results
[0382] THP-1 cells were treated and analyzed by western blot. Figures 2A-2B show that
VB-201 inhibits formation of p-IKK, p-ERK and p-p38 induced by PGN in THP-1 cells. Accordingly, VB-201 inhibits PGN (TLR2)-induced signaling.
Example 3
VB-201 Inhibits MCP-1 -Induced Signaling in human monocytes (THP-1 cell line)
Methods and Materials
Activation of cells and Western blotting
[0383] THP-1 cells (106/ml) were pretreated for 20 min with VB-201 at the doses indicated in Figure 4, or with solvent, followed by activation with 50 ng/ml MCPl, or were untreated ("Unt"). Cells were washed and resuspended in lysis buffer containing 1 : 100 dithiothreitol (DTT), phosphatase and protease inhibitors (Thermo Scientific). Samples were loaded onto a precast Criterion TGX gel (Bio-Rad, Hemel Hempstead, UK) and transferred onto nitrocellulose membrane. Blots were blocked with 5% milk or BSA in Tris buffered saline and Tween 20 (TBST) for 1 h, followed by incubation with primary and secondary antibodies. Membranes were developed using an ECL kit (Thermo Scientific). The following antibodies were used for immunoblotting:
[0384] Primary antibodies: p-ERKl/2 (Cat. No. M8159; 1 : 10000) was purchased from
Sigma (Israel). p-AKT (Cat. No. 4060; 1 : 1000) was purchased from Cell Signaling Technology (Danvers, MA). aTubulin served as a loading control and was purchased from Sigma (Israel).
[0385] Secondary antibodies: HRP donkey anti-rabbit (1 :5000) and HRP goat anti-mouse
(1 :3000) were from Jackson ImmunoRe search (West Grove, PA, USA). HRP donkey anti-goat (1 :5000) was from Santa Cruz Biotechnology.
Results
[0386] Figure 3 shows that VB-201 inhibits formation of p-AKT and p-ERK induced by
MCP-1 in THP-1 cells. Accordingly, VB-201 inhibits MCP-1 -induced signaling. Example 4
VB-201 Inhibits Chemokine-Induced Migration of human monocytes (primary
CD 14+)
Methods and Materials
Isolation of monocytes
[0387] Venous blood samples were obtained from healthy male donors in compliance with the Institutional Review Board at the Sheba Medical Center, Ramat Gan, Israel. PBMCs were isolated on Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) using 50 ml Leucosep tubes (Greiner Bio-One, Frickenhausen, Germany). Cells were washed in PBS (Kibbutz Beit Haemek, Israel) and incubated at 4 °C for 15 minutes in a buffer containing PBS and 0.5% bovine serum albumin (BSA) with human CD 14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).
Activation of cells and cell migration trans-well assay
[0388] Cells (106/ml) were pretreated for 20 min with VB-201 at the doses indicated in
Figure 5, or with solvent (Sol).
[0389] To test for chemokine-induced cell migration, RANTES (100 ng/ml; Cat. No.
300-06, PeproTech, Israel) and MCP-1 (50 ng/ml; Cat. No. 300-04, PeproTech, Israel) were dissolved in RPMI-1640 medium supplemented with 0.5% fetal bovine serum (FBS) and placed at the lower chamber of QCM 24-well, 5 mm pore, migration assay plates (Corning-Costar, Corning, NY). Cells (3 x 105) were seeded in the upper chamber and incubated for 2-4 hours. Subsequently, the number of cells which migrated to the lower compartment was determined by fluorescence-activated cell sorting (FACS).
Results
[0390] Human monocytes were treated and analyzed for cell migration by trans-well assay. Figure 4 shows that VB-201 inhibits chemokine-induced migration of human monocytes (primary CD 14+). Example 5
VB-201 Inhibits SDFl -Induced Migration in human monocytes (THP-1 cell line) Methods and Materials
[0391] THP-1 cells (106/ml) were pretreated for 20 min with VB-201 or with solvent
(Sol). To test for chemokine-induced cell migration, RANTES (100 ng/ml, Cat. No. 300- 06) (PeproTech, Israel) and MCP-1 (50 ng/ml, Cat. No. 300-04) (PeproTech, Israel) were dissolved in RPMI-1640 medium supplemented with 0.5% fetal bovine serum (FBS) and placed at the lower chamber of QCM 24-well, 5 mm pore, migration assay plates (Corning-Costar, Corning, NY). Cells (3 x 105) were seeded in the upper chamber and incubated for 2-4 hours. Subsequently, the number of cells which migrated to the lower compartment was determined by fluorescence-activated cell sorting (FACS).
Results
[0392] Figure 5 shows VB-201 inhibits SDFl -induced migration of human monocytes
(THP-1 cell line).
Example 6
VB-201 Inhibits RANTES-Induced Signaling in human monocytes (primary
CD 14+)
[0393] Human monocytes were obtained, treated and analyzed by western blot as described in Example 1 and Figure 6, except that cells were induced with RANTES (100 ng/ml; Cat. No. 300-06, PeproTech, Israel) for 15 minutes. Figure 6 shows that VB-201 inhibits formation of p-ERK induced by RANTES in human monocytes. Accordingly, VB-201 inhibits RANTES-induced signaling. Example 7
VB-201 Inhibits IL-12p40 Levels in human monocytes (primary CD 14+), stimulated by LPS (via TL 4) or Pam3CSK4 (via TLR2)
Methods and Materials
[0394] Human monocytes were seeded (106/ml) and pretreated for 1 hour with VB-201, followed by 24 hour activation with 100 ng/ml LPS from Escherichia coli strain 055:B5 (Sigma, Israel) (Figure 7A) or 300 ng/ml Pam3CSK4 (InvivoGen, San Diego, CA, USA) (Figure 7B) to induce cytokine production. IL-12/23p40 concentration in the supernatant was then measured by ELISA (R&D systems, Cat. No. DY1240). Cells activated with solvent (0.5% ethanol in PBS) were used as a control.
Results
[0395] Figures 7A-7B show that VB-201 inhibits secretion of IL-12p40 by LPS (TLR4)- stimulated and Pam3CSK4 (TLR2)-stimulated human monocytes (primary CD14+).
Example 8
VB-201 Inhibits LPS binding by Human Monocytes (primary CD 14+)
Methods and Materials
Isolation of monocytes
[0396] Venous blood samples were obtained from healthy male donors in compliance with the Institutional Review Board at the Sheba Medical Center, Ramat Gan, Israel. PBMCs were isolated on Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) using 50 ml Leucosep tubes (Greiner Bio-One, Frickenhausen, Germany). Cells were washed in PBS (Kibbutz Beit Haemek, Israel) and incubated at 4 °C for 15 minutes in a buffer containing PBS and 0.5% bovine serum albumin (BSA) with human CD 14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).
LPS binding inhibition assay
[0397] To assess interference with lipopolysaccharide (LPS) binding, VB-201 were incubated for 20 min with cells (106/ml) after which 100 ng/ml of biotin-LPS (InvivoGen) was added for an additional 15 minutes, all at 4 °C. Cells were washed, resuspended in FACS buffer and analyzed on a FACS-Calibur device.
[0398] Figure 8 shows that VB-201 inhibited the binding to human monocytes (primary
CD14+) of LPS with an IC50 of ~7μg/ml.
Example 9
VB-201 Inhibits IL-6 Secretion in LPS (LLR4)- Stimulated Monocyte-Derived Dendritic Cells (Mo-Derived DCs)
Methods and Materials
[0399] To generate monocyte-derived DC (Mo-Derived DCs), CD14+ monocytes were counted, washed and seeded (106/ml) in medium containing RPMI-1640, L-glutamine, β- mercaptoethanol, 10% fetal calf serum (FCS), sodium pyruvate, non-essential amino acids, 0.01 M HEPES, antibiotics (penicillin, streptomycin), 50 ng/ml human granulocyte-macrophage colony-stimulating factor (GMCSF) and 20 ng/ml human IL-4 (both from PeproTech Asia, Israel). Medium was replaced every 2-3 days. Mo-DCs were collected 5-6 days post-culture, counted and seeded (106/ml). Cells were pretreated for 1 hour with VB-201, followed by 24 hours activation with 100 ng/ml LPS from Escherichia coli strain 055 :B5 (Sigma, Israel) to induce cytokine production. IL-6 concentration (Figure 9) in supernatant was measured by ELISA (R&D systems, Cat. No. DY206). Cells activated with solvent (0.5% ethanol in PBS) were used as a control.
Results
[0400] Figure 9 shows VB-201 inhibits IL-6 secretion in LPS (TLR4) stimulated Mo-
Derived DCs.
Example 10
VB-201 Inhibits IL-12p40 Secretion in LPS (TLR4) Stimulated Mo-Derived DCs
[0401] Mo-Derived DCs were obtained, treated and analyzed by ELISA as described in
Eample 9 and Figure 10, except that IL-12p40 concentration in supernatant was measured by ELISA (R&D systems, cat. no DY1240). Figure 10 shows VB-201 inhibits IL-12p40 secretion in LPS (TLR4) stimulated Mo-Derived DCs.
Example 11
VB-201 Effect on Liver Inflammation and Fibrosis
Methods and Materials
Induction of NASH and liver fibrosis
[0402] Neonatal male mice exposed to low-dose streptozotocin (STZ) develop liver steatosis with diabetes. Continuous high fat diet (HFD) increases lobular inflammation with foam cell-like macrophages, showing nonalcoholic steatohepatitis (NASH) pathology. NASH was induced in 40 male mice by a single subcutaneous injection of 200 μg per mouse of STZ two days after birth and feeding HFD [57 kcal% fat]) from four weeks of age. Vehicle, VB-201 (4 mg/kg), or telmisartan (10 mg/kg) as positive control, were administered once daily for three weeks, starting from six weeks of age. Mice were sacrificed at nine weeks of age.
Steatohepatitis and fibrosis evaluation
[0403] Liver pathology was used to determine the effect of VB-201 on liver inflammation and fibrosis. Histology slides were stained with hematoxylin/eosin (H&E) to assess inflammation. The inflammation score was determined as follows:
0 - no inflammatory foci
1 - <2 inflammatory foci
2 - 2-4 inflammatory foci
3 - >4 inflammatory foci
[0404] Histology slides were stained with Sirius red to determine collagen content as a marker for the extent of fibrosis.
Results
[0405] The effects of VB-201 on liver inflammation and fibrosis in a NASH mouse model were tested. Figures 11A-11B show that disease induction resulted in notable inflammation in the liver of vehicle treated mice. Treatment with VB-201 significantly curtailed inflammation by 65%. Administration with the positive control telmisartan significantly reduced liver inflammation by 77%. Figures 12A-12B show that disease induction in Example 11 also resulted in notable increases in the fibrosis area in the liver of vehicle treated mice. The results in Figures 12A-12B demonstrate that VB-201 significantly decreased the extent of fibrosis (by about 34%) compared to the vehicle treated mice.
Example 12
VB-201 effect on Focal and Segmental Glomerulosclerosis
Methods and Materials
Animals and Experimental Protocol
[0406] Male Sprague Dawley (SD) Rats (Harlan Laboratories, Israel) with an initial weight of 200 g were housed 2-3 per cage in IVC cages in dedicated HVAC (heat, ventilation, air conditioning) animal facility. The facility had no exposure to outside light and was maintained on automatic alternating cycles of 12 hours of light and 12 hours of dark. Animals were provided with a commercial rodent diet (Harlan Teklad TRM Rat/Mouse Diet) ad libitum and allowed free access to autoclaved water, supplied to each cage via polysulphone bottles with stainless steel sipper tubes. All animal work was approved by the Animal Care and Use Committee of Israel (IL- 13 -03 -027).
Induction of Chronic Renal Disease by 5/6 Nephrectomy
[0407] Rats were divided into three groups: (1) Healthy rats (n=3) in group A, (2) Sham group - subjected to chirurgical process but without kidney mass reduction (n=3) in group B, and (3) the rest were induced with chronic renal failure (n=24). Chronic renal failure was induced by a two stage (5/6) nephrectomy (Nx), with subtraction firstly of about 2/3 of the left kidney by left flank incision and, one week later, complete removal of the right kidney. General anesthesia consisted of intraperitoneal injection of ketamine 100 mg/kg and xylazine 20 mg/kg (0.85 ml ketamine + 0.15 ml xylazine for each ml preparation; 1 μΐ/g BW was injected LP). Experimental Groups
[0408] One week following the second surgery, rats were randomly assigned to the following experimental groups:
Healthy, orally administered with vehicle - PBS 0.5% Ethanol (n=3);
Sham-operated, orally administered with vehicle - PBS 0.5% Ethanol (n=3);
Nephrectomized, orally administered with vehicle - PBS 0.5% Ethanol (n=8);
Nephrectomized, orally administered with VB-201 4 mg/kg (n=8); and
Nephrectomized, orally administered with telmisartan 10 mg/kg as positive control (n=8).
[0409] Body weight (BW) was monitored throughout the study and rats were treated by oral gavage according to their body weight for 7 weeks. Rats were sacrificed by C02 inhalation 8 weeks from removal of the right kidney (2nd surgery).
Kidney Collection
[0410] Upon sacrifice, at 8 weeks, kidneys were collected, weighed and fixed in 4% formaldehyde.
Renal Morphology and Morphometric Analysis
[0411] For light microscopy, paraffin-embedded tissue slides of 4 μπι were stained with
Periodic Acid-Schiff (PAS) reagent.
[0412] Glomerular sclerosis index. Glomerulosclerosis was assessed by PAS-stained sections using a semiquantitative scoring system. The extent of glomerulosclerosis was evaluated by examining mostly 100 randomly selected glomeruli at a magnification of x400 and applying a score system according to the percentage of sclerosed glomerular area. The score was graded from 0 to 4: (0=0% area; 1=1-25%; 2=26-50%, 3=51-75%, 4=76%) and above). The mean of all scored glomeruli was presented. Moreover, the extent of global and segmental glomerulosclerosis was evaluated in the same glomeruli, where <80%> sclerosis was referred to as segmental and >80%> was referred to as global.
[0413] Glomerular area. The glomerular area of mostly 100 randomly selected glomeruli at a magnification of xlOO was quantitated by counting squares covered by glomeruli area using a grid and the mean glomeruli area was calculated.
[0414] Immunohistochemistry. Renal tissues were fixed in 4% formaldehyde and embedded in paraffin. The paraffin-embedded tissues were then cut to form tissue slides of 4 μηι. Immunohistochemistry of the paraffin-embedded tissue slides was analyzed using antibodies in the following concentration: monoclonal mouse anti rat CD-68 (ED-1, Serotec MCA341) 1 :25. For quantitation of interstitial CD68+ staining, the number of positive cells was counted in 20 randomly selected non-overlapping fields per animal, and the mean value was presented.
[0415] Real-time PCR. Kidney RNA was extracted with an RNeasy Fibrous Tissue Mini kit (Qiagen) and after DNAse I treatment, single-stranded cDNA was synthesized from 2 μg total RNA using the qScript cDNA Synthesis Kit (Quanta Biosciences) and diluted for real-time PCR. The expression of collagen 4a, fibronectin and TGFp was quantified using the 7300 Real Time PCR System (Applied Biosystems). The assay was performed according to manufacturer instructions using the primers (Assay ID) represented at the table below supplied by Applied Biosystems. Data were normalized to the reference gene TATA-box Binding Protein (TBP) and presented as relative mRNA levels compared with Sham PBS 0.5% Eth treatment (Table 1).
Table 1 : Gene Expression references
Statistics
[0416] Data are expressed as means ± SEM. Statistical significance was determined by one-way ANOVA or Student's t-test where appropriate. Statistical analyses were performed using Sigma Stat software.
Results
VB-201 Treatment Effect on Glomerular Damage
[0417] Glomeruli were evaluated for their fibrosis extent by scoring and by calculation of the percent of glomeruli having segmental sclerosis, global sclerosis and the sum of global and segmental sclerotic glomeruli. Moreover, the area of the glomeruli was calculated and the percent of hypertrophied glomeruli was calculated. Damaged glomeruli included hypertrophied (at least xl .5 from normal area) and or sclerotic glomeruli. [0418] VB-201 and telmisartan treatment significantly reduced the damaged glomeruli by
29% (p=0.01) and 31% (p<0.005), respectively (FIG. 13). This effect was partially contributed by the reduction in glomeruli hypertrophy. The major contribution to the reduction in glomeruli damage was due to the reduction in sclerotic glomeruli. VB-201 and telmisartan treatment resulted in a 34% (p<0.05) and 57% (p<0.005) reduction of sclerotic glomeruli, respectively (FIG. 14, Table 2).
Table 2: Effect of VB-201 on Glomerular sclerosis (Mean±S.E)A
sclerosis
1.0±0.58 1.3±0.88 41.0±4.81 26.5±4.39 19.1±4.30
Segmental % (n=3) (n=3) (n=7) (n=8) (n=8)
p≤0.001 p≤0.001 P<0.05 P=0.005
0.0±0.00 0.0±0.00 7.1±4.39 5.4±3.22 1.9±1.60
Global % (n=3) (n=3) (n=7) (n=8) (n=8)
n.s n.s n.s n.s
1.0±0.58 1.3±0.88 48.3±5.38 31.8±4.92 21.0±5.45
Global &
(n=3) (n=3) (n=7) (n=8) (n=8)
Segmental %
p≤0.001 p≤0.001 P<0.05 P<0.005
*Number of animals tested per group and p value versus Nx PBS 0.5% Eth group is presented.
[0419] FIG. 15 shows typical sclerotic changes in glomeruli (PAS staining) of vehicle treated nephrectomized animals in contrast with healthy or sham operated animals or with VB-201 treated animals or telmisartan treated animals.
VB-201 Treatment Effect on Glomerular and Interstitial Monocyte/Macrophage
Infiltration
[0420] The number of monocytes/macrophages that infiltrated into the glomeruli was evaluated 8 weeks after surgery. (ED-1/CD68+) were significantly (p<0.001) higher by 11 or 4 fold, respectively, in vehicle treated nephrectomized rats (3.669±0.324), in contrast with healthy (0.320±0.040) or sham operated animals (0.880±0.139). VB-201 treatment significantly (p=0.008) reduced the number of glomerular monocytes/macrophages by 42% (2.113±0.374) compared to those observed for Nx PBS 0.5%) Eth treatment. Telmisartan treated animals had 13% non-significant reduction (3.185±0.427) compared to those observed for Nx PBS 0.5% Eth treatment. (FIG. 16A, 16C and Table 3).
Table 3 : Effect of VB-201 on Glomerular and Interstitial Monocyte/Macrophage
*Number of animals tested per group and p value versus Nx PBS 0.5% Eth group is presented.
[0421] The number of interstitial monocytes/macrophages examined 8 weeks after surgery (ED-1/CD68+) were significantly (p=0.005) higher by 7 or 6 fold, respectively, in vehicle treated nephrectomized rats (527.9±72.93), in contrast with healthy (79.0±7.77) or sham operated animals (86.67±16.18). VB-201 treatment significantly (p<0.005) reduced the number of interstitial monocytes/macrophages by 49% (269.25±25.41) compared to those observed for Nx PBS 0.5% Eth treatment. Telmisartan treatment reduced the number of interstitial monocytes/macrophages by 20% (421.0±61.77) compared to those observed for Nx PBS 0.5% Eth treatment (FIG. 16B and Table 3).
VB-201 Treatment Effect on Pro-fibrotic Markers
[0422] The mRNA expression of Collagen IV was increased significantly by 7 or 8 fold, respectively, in vehicle treated nephrectomized rats (7.5±1.51), in contrast with healthy (1.1±0.12) or sham operated animals (1.0±0.32). VB-201 treatment significantly (p<0.05) reduced Collagen IV expression by 42% (4.3±0.33) compared to those observed for Nx PBS 0.5%) Eth treatment. A 41%> reduction in Collagen IV expression was observed in the telmisartan treated nephrectomized rats (4.4±0.23) compared to those observed for Nx PBS 0.5% Eth treatment, with marginal significance (p=0.064) (FIG. 17A).
[0423] The mRNA expression of TGF-β was increased significantly by 10 or 8 fold, respectively, in vehicle treated nephrectomized rats (8.4±0.49), in contrast with healthy (0.9±0.24) or sham operated animals (l .OtO.23) (p<0.001). VB-201 and telmisartan treatment significantly (p<0.001) reduced TGF-β expression by 37% (5.3±0.33) and 44% (4.7±0.52), respectively, compared to those observed for Nx PBS 0.5% Eth treatment (FIG. 17B).
Example 13
VB-201 Inhibits Expression of IL-12/23p40 in Livers of NASH-Induced Mice
[0424] NASH-induced mice were orally administered VB-201 at a dose of 4 mg/kg or telmisartan at a dose of 10 mg/kg once daily from Week 6 to Week 9. RNA was prepared from livers from normal mice and NASH-induced mice treated with vehicle, VB-201, or telmisartan, using RNeasy mini kit (Qiagen). For cDNA preparation, 2 μg of RNA was combined with the qScript reaction mix and qScript Reverse Transcriptase (Quanta Biosciences) for 5 min at 22° C and then for 30 min at 42° C. The reaction was ended by incubation for an additional 5 min at 85° C. All real time PCR reactions were performed using the 7300 Real Time PCR System (Applied Biosy stems). Q-PCR was performed with sets of probe with primer for mouse IL-12/23p40 (Applied Biosystems). GAPDH was used to normalize RNA levels.
[0425] FIG. 18 shows that VB-201 inhibits IL-12/23p40 expression in livers of NASH- induced mice. Analysis of IL-12/23p40 in the livers of NASH-induced mice shows that VB-201 significantly attenuated the expression of IL-12/23p40.
[0426] All publications, patents and patent applications mentioned in this application are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.

Claims

WHAT IS CLAIMED IS:
1. A method of treating or preventing fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having a structure according to Formula 1 :
Formula 1 wherein: n is an integer from 1 to 6, wherein when n is 1, Cn, Bn, Rn, and Y are absent, and C1 is attached to R'n; each of Bi, B2, ...Bn-1 and Bn is independently selected from the group consisting of oxygen, sulfur, nitrogen, phosphorus and silicon, whereby each of said nitrogen, phosphorus and silicon is substituted by at least one substituent selected from the group consisting of hydrogen, lone pair electrons, alkyl, halo, cycloalkyl, aryl, hydroxy, thiohydroxy, alkoxy, aryloxy, thioaryloxy, thioalkoxy and oxo; each of Ai, A2, ...An-1 and An is independently selected from the group consisting of CR"R"\ C=0 and C=S,
Y is selected from the group consisting of hydrogen, acyl, alkyl, aryl, cycloalkyl, carboxy, saccharide, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-glutaric acid, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-biphosphonate, phosphoinositol-4,5- bisphosphate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol and a moiety having the general formula:
wherein: each of B' and B" is independently selected from the group consisting of sulfur and oxygen; and each of D' and D" is independently selected from the group consisting of hydrogen, alkyl, amino substituted alkyl, cycloalkyl, phosphonate and thiophosphonate; and each of Xi, X2, ...Xn-1 is independently a saturated or unsaturated hydrocarbon having the general Formula 2:
Ra Rb Rm-1 Rm
-Ca Cb- -C m-1 Cm Z
R'a R'b R'm-1 R'm
Formula 2 wherein m is an integer from 1 to 26; and
Z is selected from the group consisting of:
R"
OR" R"
R" w=c /
\ w=c — 1 CH
w=
H, \ o I W '" and -OR wherein W is selected from the group consisting of oxygen and sulfur; wherein at least one of Xi, X2, ...Xn-1 comprises a Z other than hydrogen, and wherein: each of Ri, R'i, R2, ... Rn-1, Rn, Rn, each of R" and R" and each of Ra, Ra, Rb, Rb, ...Rm-1, Rm-1, Rm and Rm is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, halo, trihalomethyl, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, phosphonate, phosphate, phosphinyl, sulfonyl, sulfinyl, sulfonamide, amide, carbonyl, thiocarbonyl, C-carboxy, O-carboxy, C-carbamate, N- carbamate, C-thiocarboxy, S-thiocarboxy and amino, or, alternatively, at least two of Ri, R'i, R2, ...Rn-1, Rn and Rn and/or at least two of Ra, Ra, Rb, Rb, ...Rm-1, Rm-1, Rm and Rm form at least one four-, five- or six-membered aromatic, heteroaromatic, alicyclic or heteroalicyclic ring; wherein the fibrosis is pulmonary fibrosis, skin fibrosis, kidney fibrosis, cystic fibrosis, progressive massive fibrosis, cirrhosis, steatohepatitis, nonalcoholic fatty liver disease, endomyocardial fibrosis, atrial fibrosis, medastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, nephrogenic systemic fibrosis, keloid, arthrofibrosis, Peyronie's disease, Dupuytren's contracture, adhesive capsulitis, or focal and segmental glomerulosclerosis.
2. The method of claim 1, wherein the compound is l-hexadecyl-2-(4'- carboxybutyl)-glycero-3-phosphocholine.
3. The method of claim 1 or 2, wherein the subject is a human.
4. The method of any one of claims 1-3, wherein activity of TLR2, TLR4, or CD14 is inhibited in a cell of the subject.
5. The method of any one of claims 1-3, wherein activity of TLR2 and TLR4; activity of TLR4 and CD 14; activity of TLR2 and CD 14; or activity of TLR2, TLR4, and CD 14 is inhibited in a cell of the subject.
6. The method of any one of claims 1-5, wherein liver lobular formation is reduced in the subject.
7. The method of any one of claims 1-6, wherein the compound is (R)-l-hexadecyl- 2-(4'-carboxybutyl)-sn-glycero-3-phosphocholine.
8. The method of any one of claims 1-7, wherein the compound is a pharmaceutically acceptable salt, a hydrate, or a solvate.
9. A method of treating or preventing liver fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of l-hexadecyl-2-(4'-carboxybutyl)- gly cero-3 -phosphocholine .
10. The method of claim 9, wherein the l-hexadecyl-2-(4'-carboxybutyl)-gly cero-3 - phosphocholine is the R- isomer.
11. The method of claim 9 or 10, wherein the subject is a human.
12. The method of any one of claims 9-11, wherein activity of TLR2, TLR4, or CD14 is inhibited in a cell of the subject.
13. The method of any one of claims 9-12, wherein activity of TLR2 and TLR4; activity of TLR4 and CD 14; activity of TLR2 and CD 14; or activity of TLR2, TLR4, and CD 14 is inhibited in a cell of the subject.
14. The method of any one of claims 9-13, wherein liver lobular formation is reduced in the subject.
15. The method of any one of claims 9-14, wherein the l-hexadecyl-2-(4'- carboxybutyl)-glycero-3-phosphocholine is in the form of a pharmaceutically acceptable salt, a hydrate, or a solvate.
16. A method of treating or preventing kidney fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of l-hexadecyl-2-(4'-carboxybutyl)- gly cero-3 -phosphocholine .
17. The method of claim 16, wherein the l-hexadecyl-2-(4'-carboxybutyl)-gly cero-3 - phosphocholine is the R- isomer.
18. The method of claim 16 or 17, wherein the subject is a human.
19. The method of any one of claims 16-18, wherein the kidney fibrosis is focal and segmental glomerulosclerosis.
20. The method of any one of claims 16-19, wherein activity of TLR2, TLR4, or CD 14 is inhibited in a cell of the subject.
21. The method of any one of claims 16-20, wherein activity of TLR2 and TLR4; activity of TLR4 and CD 14; activity of TLR2 and CD 14; or activity of TLR2, TLR4, and CD 14 is inhibited in a cell of the subject.
22. The method of any one of claims 16-21, wherein the l-hexadecyl-2-(4'- carboxybutyl)-glycerol-3-phosphocholine is in the form of a pharmaceutically acceptable salt, a hydrate, or a solvate.
EP15863247.1A 2014-11-26 2015-11-26 Oxidized lipids and treatment or prevention of fibrosis Active EP3223824B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085051P 2014-11-26 2014-11-26
PCT/IB2015/059133 WO2016084023A1 (en) 2014-11-26 2015-11-26 Oxidized lipids and treatment or prevention of fibrosis

Publications (3)

Publication Number Publication Date
EP3223824A1 true EP3223824A1 (en) 2017-10-04
EP3223824A4 EP3223824A4 (en) 2018-01-24
EP3223824B1 EP3223824B1 (en) 2021-01-06

Family

ID=56073713

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15863247.1A Active EP3223824B1 (en) 2014-11-26 2015-11-26 Oxidized lipids and treatment or prevention of fibrosis

Country Status (8)

Country Link
US (2) US10022388B2 (en)
EP (1) EP3223824B1 (en)
JP (1) JP6717825B2 (en)
CN (1) CN106999506A (en)
CA (1) CA2968790A1 (en)
ES (1) ES2855299T3 (en)
IL (1) IL252509B (en)
WO (1) WO2016084023A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968790A1 (en) 2014-11-26 2016-06-02 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
CN113307824B (en) * 2021-04-26 2022-05-27 浙江大学 Amphiphilic material and application thereof in preparation of liposome

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5638578B2 (en) 1973-05-18 1981-09-08
US4100444A (en) 1975-09-29 1978-07-11 General Electric Company Dynamoelectric machine winding arrangement
US4166132A (en) 1977-08-18 1979-08-28 Pfizer Inc. Antiviral amine derivatives of glycerol and propanediols
GB1572226A (en) 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
JPS58154512A (en) 1982-03-09 1983-09-14 Takeda Chem Ind Ltd Agent for suppressing blood platelet activation factor
JPS5993022A (en) 1982-11-16 1984-05-29 Kao Corp Polyol ether compound, its preparation and cosmetic containing the same
DE3307925A1 (en) 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln NEW 0-ACYL-ALKANDIOL PHOSPHOLIPIDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
US4614796A (en) 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (en) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd Novel glycerin derivative, its preparation and drug containing it
JPS60104066A (en) 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd Glycerin derivative, its preparation, and drug containing it
AT383130B (en) 1984-05-15 1987-05-25 Chemie Linz Ag METHOD FOR THE PRODUCTION OF PHOSPHATIDYLCHOLINES AND PHOSPHATIDYLETHANOLAMINES SUBSTITUTED DIFFERENTLY AT C1 AND C2 OVER THE NEW COMPOUNDS 1-0-TRITYLGLYCEROPHOSPHOCHOLIN OR RELATED (1-0, N-DITYHOHOLINE)
JPH0617307B2 (en) 1984-11-09 1994-03-09 武田薬品工業株式会社 Antitumor agent
US4710579A (en) 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
US4827011A (en) 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
EP0225129B1 (en) 1985-11-29 1989-05-24 Takeda Chemical Industries, Ltd. Phospholipid derivatives, their production and use
US5061626A (en) 1986-03-24 1991-10-29 University Of Sydney Antigenic anarogues of platelet activating factor
AU7285487A (en) 1986-04-07 1987-11-09 Upjohn Company, The Anthelmintic quaternaryalkyl acylhydrazones, method of use and compositions
JPS6294A (en) 1986-05-09 1987-01-06 Toyama Chem Co Ltd Novel glycerophosphoric acid derivative and salt and production thereof
JP2512311B2 (en) 1986-07-14 1996-07-03 日本ケミファ株式会社 Novel glycerin derivative and antihypertensive agent
JPS6354386A (en) 1986-08-26 1988-03-08 Takeda Chem Ind Ltd Phospholipid and use thereof
JPS63135395A (en) 1986-11-28 1988-06-07 Nippon Oil & Fats Co Ltd Phospholipid derivative and production thereof
DE3807123A1 (en) 1988-03-04 1989-09-14 Boehringer Mannheim Gmbh SUBSTRATE FOR PHOSPHOLIPASES
JPH01258691A (en) 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd Phospholipid derivative and production thereof
JP2534894B2 (en) 1988-06-24 1996-09-18 日本ケミファ株式会社 Novel glycerin derivative and antihypertensive agent containing the derivative
JPH0248585A (en) 1988-08-10 1990-02-19 Nippon Oil & Fats Co Ltd Phospholipid derivative and production thereof
CA2001401A1 (en) 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
JPH03258740A (en) 1990-03-06 1991-11-19 Kao Corp Liquid oil, production thereof and cosmetic containing same oil
ES2019552A6 (en) 1990-04-11 1991-06-16 Menarini Lab Process for the preparation of glycerophospholipids
JP2869572B2 (en) 1990-05-14 1999-03-10 和光純薬工業株式会社 Method for producing phosphatidylcholine derivative
JPH0754187B2 (en) 1991-07-31 1995-06-07 株式会社フジマック Batch type combined heating device
JP3128782B2 (en) 1992-06-12 2001-01-29 科学技術振興事業団 Method for producing crosslinked polymer thin film
US5561052A (en) 1992-06-18 1996-10-01 Koike; Katsumasa Process for detecting oxidized lipids and process for forming oxidized lipids
FR2714382B1 (en) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipids vector of active molecule, their preparation and their use in cosmetic or dermatological compositions.
AU1751795A (en) 1994-03-04 1995-09-18 University Of British Columbia, The Liposome compositions and methods for the treatment of atherosclerosis
JP3364313B2 (en) 1994-03-22 2003-01-08 株式会社トクヤマ Porphyrin / indium complex and anion-sensitive membrane
JPH0859545A (en) 1994-08-24 1996-03-05 Kao Corp Carboxyethyl ether derivative and detergent composition containing the same
DE69535758D1 (en) 1994-08-29 2008-07-03 Univ Wake Forest LIPID ANALOGUE FOR THE TREATMENT OF VIRAL INFECTIONS
JPH08208548A (en) 1995-02-01 1996-08-13 Kao Corp Production of glycerol derivative
US5660855A (en) 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6261597B1 (en) 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
JP3781877B2 (en) 1997-10-03 2006-05-31 株式会社ムック Ascorbic acid derivatives or salts thereof, and pharmaceuticals
US6414168B1 (en) 1998-12-28 2002-07-02 Caschem, Inc. Epoxidation of ricinic compounds using a phase-transfer catalyst
US6348583B1 (en) 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
AU2427601A (en) 1999-11-30 2001-06-12 Arizona Board Of Regents On Behalf Of The University Of Arizona, The Radiation sensitive liposomes
ES2250378T3 (en) 2000-03-31 2006-04-16 The Regents Of The University Of California FUNCTIONAL TEST OF HIGH DENSITY LIPOPROTEIN.
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
WO2002041827A2 (en) 2000-11-24 2002-05-30 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
DE10155095A1 (en) 2001-11-09 2003-05-22 Cognis Deutschland Gmbh ylglycerinethercarbonsäuren alkyl (s)
EP2604614B1 (en) 2004-07-09 2016-03-09 Vascular Biogenics Ltd. Oxidized phospholipids
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US20060194765A1 (en) 2004-11-16 2006-08-31 Garcia Joe G N Methods and compositions using oxidized phospholipids
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US8252775B2 (en) 2005-07-21 2012-08-28 The Board Of Trustees Of The Leland Stanford Junior University Method of treating multiple sclerosis with phosphocholine containing lipids
US8084209B2 (en) 2005-07-22 2011-12-27 Children's Hospital & Research Center Oakland HMGCR isoforms in prediction of efficacy and identification of cholesterol-modulating compounds
US20090074720A1 (en) 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US8137977B2 (en) 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
JP2008037763A (en) 2006-08-01 2008-02-21 Adeka Corp Antibacterial agent and antibacterial agent composition
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
EP2111105A4 (en) 2007-11-28 2011-05-04 Method of delaying the onset of clinically definite multiple sclerosis
EP2348864A4 (en) 2008-10-08 2013-07-31 Vascular Biogenics Ltd Oxidized thiophospholipid compounds and uses thereof
KR20110095288A (en) 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 Oxidized lipid compounds and uses thereof
JP6196040B2 (en) 2010-01-05 2017-09-13 バスキュラー バイオジェニックス リミテッド Usage of specific anti-angiogenic adenoviral agents
US20120329758A1 (en) 2010-01-05 2012-12-27 Yael Cohen Combined Treatment Utilizing VB-201
WO2011083466A1 (en) 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Compositions and methods for treating glioblastoma gbm
WO2013033642A1 (en) 2011-09-01 2013-03-07 Vascular Biogenics Ltd. Formulations and dosage forms of oxidized phospholipids
EP2791101B1 (en) * 2011-12-12 2019-09-18 Vascular Biogenics Ltd. Treatment of non-alcoholic steatohepatitis
WO2013121300A2 (en) * 2012-02-16 2013-08-22 Vascular Biogenics Ltd. Methods for treating psoriasis and vascular inflammation
CA2968790A1 (en) * 2014-11-26 2016-06-02 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of fibrosis
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids

Also Published As

Publication number Publication date
JP6717825B2 (en) 2020-07-08
ES2855299T3 (en) 2021-09-23
US20180325928A1 (en) 2018-11-15
IL252509B (en) 2020-06-30
WO2016084023A1 (en) 2016-06-02
US10206936B2 (en) 2019-02-19
CA2968790A1 (en) 2016-06-02
EP3223824B1 (en) 2021-01-06
JP2017535582A (en) 2017-11-30
EP3223824A4 (en) 2018-01-24
US10022388B2 (en) 2018-07-17
IL252509A0 (en) 2017-07-31
US20170258818A1 (en) 2017-09-14
CN106999506A (en) 2017-08-01

Similar Documents

Publication Publication Date Title
Che et al. A comparative study of EPA-enriched ethanolamine plasmalogen and EPA-enriched phosphatidylethanolamine on Aβ 42 induced cognitive deficiency in a rat model of Alzheimer's disease
JP6389190B2 (en) Solid solution composition and use in chronic inflammation
EP2970089B1 (en) Substituted aromatic compounds
Sun et al. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia
EP2791101B1 (en) Treatment of non-alcoholic steatohepatitis
US10206936B2 (en) Oxidized lipids and treatment or prevention of fibrosis
Brehm et al. Cathepsin G degradation of phospholipid transfer protein (PLTP) augments pulmonary inflammation
Uhlig et al. Sphingolipids in acute lung injury
US10464957B2 (en) Oxidized lipids and methods of use thereof
Ocak et al. Inhibition of mast cell tryptase attenuates neuroinflammation via PAR-2/p38/NFκB pathway following asphyxial cardiac arrest in rats
JP2023538626A (en) N-acyl amino acid products and uses
O'Callaghan et al. Re-Examining the Role of Pulmonary Lipids in the Pathogenesis of Pulmonary Fibrosis
Di Gioia et al. Host-derived oxidized phospholipids initiate effector-triggered immunity fostering lethality upon microbial encounter.
Ouellet et al. Balsam Poplar (Populus Balsamifera), a Traditional Eastern James Bay Cree Medicine, Exerts a Limited Modulation of Intestinal Lipid Homeostasis in an Animal Model of Diet-Induced Obesity.”
ES2949940T3 (en) Compounds for use in the prevention and/or treatment of nonalcoholic hepatic steatosis and nonalcoholic steatohepatitis
WO2023199010A1 (en) Treatment of muscle fibrosis
WO2022236173A1 (en) Treating liver disease
Riboni Sphingolipids in Inflammation: From Bench to Bedside
Castro-Rivera Adenosine A2A Receptor Stimulation Enhances Mitochondrial Metabolism and Mitigates Reactive Oxygen Species-Mediated Mitochondrial Injury in the Context of Osteoarthritis
CA3195484A1 (en) Method of preventing kidney injury disruption of intestinal lymphatics
Sun et al. Articles in PresS. Am J Physiol Cell Physiol (April 27, 2016). doi: 10.1152/ajpcell. 00344.2015
Benesch Autotaxin and Tumor-Promoting Inflammation
Zhang Protective mechanisms of apoA-I mimetic peptide action in sepsis-induced tissue injury

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170626

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MENDEL, ITZHAK

Inventor name: SALEM, YANIV

Inventor name: BREITBART, EYAL

Inventor name: YACOV, NIVA

A4 Supplementary search report drawn up and despatched

Effective date: 20180103

RIC1 Information provided on ipc code assigned before grant

Ipc: C07F 9/10 20060101AFI20171220BHEP

Ipc: A61P 43/00 20060101ALI20171220BHEP

Ipc: A61K 31/685 20060101ALI20171220BHEP

Ipc: A61P 29/00 20060101ALI20171220BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180622

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VASCULAR BIOGENICS LTD.

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015064585

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031661000

Ipc: A61K0031685000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/16 20060101ALI20200525BHEP

Ipc: A61P 29/00 20060101ALI20200525BHEP

Ipc: A61K 31/685 20060101AFI20200525BHEP

Ipc: A61P 43/00 20060101ALI20200525BHEP

Ipc: A61P 9/00 20060101ALI20200525BHEP

Ipc: A61P 13/12 20060101ALI20200525BHEP

Ipc: A61P 17/00 20060101ALI20200525BHEP

Ipc: C07F 9/10 20060101ALI20200525BHEP

Ipc: A61P 7/00 20060101ALI20200525BHEP

Ipc: A61P 17/02 20060101ALI20200525BHEP

Ipc: A61P 11/00 20060101ALI20200525BHEP

Ipc: A61P 19/02 20060101ALI20200525BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200721

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1351606

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210115

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015064585

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: STOLMAR AND PARTNER INTELLECTUAL PROPERTY S.A., CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1351606

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210106

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210506

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210406

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210407

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210406

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2855299

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20210923

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210506

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015064585

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

26N No opposition filed

Effective date: 20211007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20221118

Year of fee payment: 8

Ref country code: NL

Payment date: 20221118

Year of fee payment: 8

Ref country code: LU

Payment date: 20221118

Year of fee payment: 8

Ref country code: IT

Payment date: 20221124

Year of fee payment: 8

Ref country code: IE

Payment date: 20221121

Year of fee payment: 8

Ref country code: GB

Payment date: 20221125

Year of fee payment: 8

Ref country code: FR

Payment date: 20221129

Year of fee payment: 8

Ref country code: DE

Payment date: 20220620

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20221122

Year of fee payment: 8

Ref country code: BE

Payment date: 20221118

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230125

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20151126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602015064585

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20231201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231130

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20231126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231126

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231130

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20231130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231201

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231201

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210106

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240601

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231126

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231130